

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 255/37, 235/32, 69/612, 62/10, 49/175, A61K 31/275, 31/215, 31/19, 31/16, 31/12		A1	(11) International Publication Number: WO 98/06692
			(43) International Publication Date: 19 February 1998 (19.02.98)
(21) International Application Number: PCT/US97/14098		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 August 1997 (11.08.97)			
(30) Priority Data: 08/695,599 12 August 1996 (12.08.96) US			
(71) Applicant (for all designated States except US): CELGENE CORPORATION [US/US]; 7 Powder Horn Drive, Warren, NJ 07059 (US).			
(71)(72) Applicants and Inventors: MULLER, George, W. [US/US]; 250 Windmill Court, Bridgewater, NJ 08807 (US). SHIRE, Mary [IE/US]; 8 Stone Street, North Plainfield, NJ 07060 (US).			
(74) Agents: COLLINS, Bruce, M. et al.; Mathews, Collins, Shepherd & Gould, P.A., Suite 306, 100 Thanet Circle, Princeton, NJ 08540-3674 (US).			

(54) Title: NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS

(57) Abstract

Cyano and carboxy derivatives of substituted styrenes of formula (I), in which Y is -CO₂, -C≡N, or lower alkyl of 1 to 5 carbon atoms; Z is -OH, -NR⁶R⁶, -R⁷, or -OR⁷; X, R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ have the values given in the description are inhibitors of tumor necrosis factor α , nuclear factor κ B, and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is 3,3-bis-(3,4-dimethoxyphenyl)acrylonitrile.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS**Background of the Invention**

This invention relates to a method of reducing the level of cytokines and their precursors in mammals and to compounds and compositions useful therein. In particular, 5 the invention pertains to a class of compounds which mediate the action of phosphodiesterases, particularly PDE III and PDE IV, and the formation of TNF α and NF κ B.

Tumor necrosis factor alpha, (TNF α) is a cytokine which is released primarily by mononuclear phagocytes in response to immunostimulators. When administered to 10 animals or humans, TNF α can cause inflammation, fever, cardiovascular effects, hemorrhage, coagulation, and acute phase responses similar to those seen during acute infections and shock states.

The nuclear factor κ B (NF κ B) is a pleiotropic transcriptional activator (Lenardo, *et al.*, *Cell* 1989, **58**, 227-29) which has been implicated in a variety of disease and 15 inflammatory states. NF κ B is thought to regulate cytokine levels including, but not limited to, TNF α and to be an activator of HIV transcription (Dbaibo *et al.*, *J. Biol. Chem.* 1993, 17762-66; Duh *et al.*, *Proc. Natl. Acad. Sci.* 1989, **86**, 5974-78; Bachelerie *et al.*, *Nature* 1991, **350**, 709-12; Boswas *et al.*, *J. Acquired Immune Deficiency Syndrome* 1993, **6**, 778-786; Suzuki *et al.*, *Biochem. And Biophys. Res. Comm.* 1993, **193**, 277-83; Suzuki 20 *et al.*, *Biochem. And Biophys. Res Comm.* 1992, **189**, 1709-15; Suzuki *et al.*, *Biochem. Mol. Bio. Int.* 1993, **31**(4), 693-700; Shakhov *et al.* 1990, **171**, 35-47; and Staal *et al.*, *Proc. Natl. Acad. Sci. USA* 1990, **87**, 9943-47). Thus, inhibition of NF κ B binding can regulate transcription of cytokine gene(s) and through this modulation and other mechanisms be useful in the inhibition of a multitude of disease states. TNF α and NF κ B 25 levels are influenced by a reciprocal feedback loop.

Many cellular functions are mediated by levels of adenosine 3',5'-cyclic monophosphate (cAMP). Such cellular functions can contribute to inflammatory conditions and diseases including asthma, inflammation, and other conditions (Lowe and Cheng, *Drugs of the Future*, **17**(9), 799-807, 1992). It has been shown that the elevation 30 of cAMP in inflammatory leukocytes inhibits their activation and the subsequent release of inflammatory mediators, including TNF α and NF κ B. Increased levels of cAMP also leads to the relaxation of airway smooth muscle. The primary cellular mechanism for the inactivation of cAMP is the breakdown of cAMP by a family of isoenzymes referred to as

cyclic nucleotide phosphodiesterases (PDE), of which seven are known. It is recognized, for example, that the inhibition of PDE type IV is particularly effective in both the inhibition of inflammatory mediator release and the relaxation of airway smooth muscle. Thus, compounds which inhibit PDE IV exhibit the desirable inhibition of inflammation and relaxation of airway smooth muscle with a minimum of unwanted side effects, such as cardio-vascular or anti-platelet effects. It is now known that inhibition of TNF α production is a consequence of inhibition of PDE IV. L.J. Lombardo, *Current Pharmaceutical design*, 1, 255-268 (1995).

Excessive or unregulated TNF α production has been implicated in a number of disease conditions. These include endotoxemia and/or toxic shock syndrome {Tracey *et al.*, *Nature* 330, 662-664 (1987) and Hinshaw *et al.*, *Circ. Shock* 30, 279-292 (1990)}; cachexia {Dezube *et al.*, *Lancet*, 335 (8690), 662 (1990)}; and Adult Respiratory Distress Syndrome (ARDS) where TNF α concentrations in excess of 12,000 pg/milliliters have been detected in pulmonary aspirates from ARDS patients {Millar *et al.*, *Lancet* 2 (8665), 712-714 (1989)}. Systemic infusion of recombinant TNF α also resulted in changes typically seen in ARDS {Ferrai-Baliviera *et al.*, *Arch. Surg.* 124(12), 1400-1405 (1989)}.

TNF α also appears to be involved in bone resorption diseases, including arthritis where it has been determined that when activated, leukocytes will produce a bone-resorbing activity, and data suggests that TNF α contributes to this activity {Bertolini *et al.*, *Nature* 319, 516-518 (1986) and Johnson *et al.*, *Endocrinology* 124(3), 1424-1427 (1989)}. It has been determined that TNF α stimulates bone resorption and inhibits bone formation *in vitro* and *in vivo* through stimulation of osteoblast formation and activation in combination with inhibition of osteoblast function. Although TNF α may be involved in many bone resorption diseases, including arthritis, the most compelling link with disease is the association between production of TNF α by tumor or host tissues and malignancy associated hypercalcemia {Calci. Tissue Int. (US) 46 (Suppl.), S3-10 (1990)}. In Graft versus Host Reaction, increased serum TNF α levels have been associated with major complications following acute allogenic bone marrow transplants {Holler *et al.*, *Blood*, 75(4), 1011-1016 (1990)}.

Cerebral malaria is a lethal hyperacute neurological syndrome associated with high blood levels of TNF α and is the most severe complication occurring in malaria patients. Levels of serum TNF α correlated directly with the severity of the disease and the

prognosis in patients with acute malaria attacks {Grau *et al.*, *N. Engl. J. Med.* **320** (24), 1586-1591 (1989)}.

Macrophage-induced angiogenesis is known to be mediated by TNF α . Leibovich *et al.* {*Nature*, **329**, 630-632 (1987)} showed TNF α induces *in vivo* capillary blood vessel formation in the rat cornea and the developing chick chorioallantoic membranes at very low doses and suggest TNF α is a candidate for inducing angiogenesis in inflammation, wound repair, and tumor growth. TNF α production also has been associated with cancerous conditions, particularly induced tumors {Ching *et al.*, *Brit. J. Cancer*, (1955) **72**, 339-343, and Koch, *Progress in Medicinal Chemistry*, **22**, 166-242 (1985)}.

TNF α also appears to play a role in the area of chronic pulmonary inflammatory diseases. The deposition of silica particles leads to silicosis, a disease of progressive respiratory failure caused by a fibrotic reaction. Antibodies to TNF α completely blocked the silica-induced lung fibrosis in mice {Pignet *et al.*, *Nature*, **344**:245-247 (1990)}. High levels of TNF α production (in the serum and in isolated macrophages) have been demonstrated in animal models of silica and asbestos induced fibrosis {Bissonnette *et al.*, *Inflammation* **13**(3), 329-339 (1989)}. Alveolar macrophages from pulmonary sarcoidosis patients have also been found to spontaneously release massive quantities of TNF α as compared with macrophages from normal donors {Baughman *et al.*, *J. Lab. Clin. Med.* **115** (1), 36-42 (1990)}.

TNF α is also implicated in the inflammatory response which follows reperfusion, called reperfusion injury, and is a major cause of tissue damage after loss of blood flow {Vedder *et al.*, *PNAS* **87**, 2643-2646 (1990)}. TNF α also alters the properties of endothelial cells and has various pro-coagulant activities, such as producing an increase in tissue factor pro-coagulant activity and suppression of the anticoagulant protein C pathway as well as down-regulating the expression of thrombomodulin {Sherry *et al.*, *J. Cell Biol.* **107**, 1269-1277 (1988)}. TNF α has pro-inflammatory activities which together with its early production (during the initial stage of an inflammatory event) make it a likely mediator of tissue injury in several important disorders including but not limited to, myocardial infarction, stroke and circulatory shock. Of specific importance may be TNF α -induced expression of adhesion molecules, such as intercellular adhesion molecule

(ICAM) or endothelial leukocyte adhesion molecule (ELAM) on endothelial cells {Munro *et al.*, *Am. J. Path.* **135** (1), 121-132 (1989)}.

TNF α blockage with monoclonal anti-TNF α antibodies has been shown to be beneficial in rheumatoid arthritis {Elliot *et al.*, *Int. J. Pharmac.* 1995 **17**(2), 141-145}.
5 High levels of TNF α are associated with Crohn's disease {von Dullemen *et al.*, *Gastroenterology*, 1995 **109**(1), 129-135} and clinical benefit has been achieved with TNF α antibody treatment, thus confirming the importance of TNF α in the disease.

Moreover, it is now known that TNF α is a potent activator of retrovirus replication including activation of HIV-1. {Duh *et al.*, *Proc. Nat. Acad. Sci.* **86**, 5974-5978 (1989);
10 Poll *et al.*, *Proc. Nat. Acad. Sci.* **87**, 782-785 (1990); Monto *et al.*, *Blood* **79**, 2670 (1990);
Clouse *et al.*, *J. Immunol.* **142**, 431-438 (1989); Poll *et al.*, *AIDS Res. Hum. Retrovirus*,
191-197 (1992)}. AIDS results from the infection of T lymphocytes with Human
15 Immunodeficiency Virus (HIV). At least three types or strains of HIV have been
identified, *i.e.*, HIV-1, HIV-2 and HIV-3. As a consequence of HIV infection, T-cell
mediated immunity is impaired and infected individuals manifest severe opportunistic
infections and/or unusual neoplasms. HIV entry into the T lymphocyte requires T
lymphocyte activation. Other viruses, such as HIV-1 and HIV-2, infect T lymphocytes
after T cell activation and such virus protein expression and/or replication is mediated or
20 maintained by such T cell activation. Once an activated T lymphocyte is infected with
HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV
gene expression and/or HIV replication. Cytokines, specifically TNF α , are implicated in
activated T-cell mediated HIV protein expression and/or virus replication by playing a role
in maintaining T lymphocyte activation. Therefore, interference with cytokine activity
such as by prevention or inhibition of cytokine production, notably TNF α , in a HIV-
25 infected individual aids in limiting the maintenance of T lymphocyte activation caused by
HIV infection.

Monocytes, macrophages, and related cells, such as kupffer and glial cells, have also
been implicated in maintenance of the HIV infection. These cells, like T cells, are targets
for viral replication and the level of viral replication is dependent upon the activation state
30 of the cells {Rosenberg *et al.*, *The Immunopathogenesis of HIV Infection*, Advances in
Immunology, **57** (1989)}. Cytokines, such as TNF α , have been shown to activate HIV
replication in monocytes and/or macrophages {Poli *et al.* *Proc. Natl. Acad. Sci.*, **87**, 782-
784 (1990)}, therefore, prevention or inhibition of cytokine production or activity aids in

limiting HIV progression as stated above for T cells. Additional studies have identified TNF α as a common factor in the activation of HIV *in vitro* and has provided a clear mechanism of action via a nuclear regulatory protein found in the cytoplasm of cells (Osborn, *et al.*, *PNAS* **86**, 2336-2340). This evidence suggests that a reduction of TNF α synthesis may have an antiviral effect in HIV infections, by reducing the transcription and thus virus production.

AIDS viral replication of latent HIV in T cell and macrophage lines can be induced by TNF α {Folks *et al.*, *PNAS* **86**, 2365-2368 (1989)}. A molecular mechanism for the virus inducing activity is suggested by TNF α 's ability to activate a gene regulatory protein (NF κ B) found in the cytoplasm of cells, which promotes HIV replication through binding to a viral regulatory gene sequence (LTR) {Osborn *et al.*, *PNAS* **86**, 2336-2340 (1989)}. TNF α in AIDS associated cachexia is suggested by elevated serum TNF α and high levels of spontaneous TNF α production in peripheral blood monocytes from patients {Wright *et al.*, *J. Immunol.* **141** (1), 99-104 (1988)}.

TNF α has been implicated in other viral infections, such as the cytomegalia virus (CMV), influenza virus, adenovirus, and the herpes family of viruses for similar reasons as those noted.


It is recognized that suppression of the effects of TNF α can be beneficial in a variety of conditions and in the past, steroids such as dexamethasone and prednisone as well as polyclonal and monoclonal antibodies {Beutler *et al.*, *Science* **234**, 470-474 (1985); WO 92/11383} have been employed for this purpose. Conditions in which the inhibition of TNF α is desirable include septic shock, sepsis, endotoxic shock, hemodynamic shock and sepsis syndrome, post ischemic reperfusion injury, malaria, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, opportunistic infections in AIDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic conditions, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ENL in leprosy, radiation damage, asthma, and hyperoxic alveolar injury.

The suppression of the action of NF κ B in the nucleus can be useful in the treatment of a variety of diseases including but not limited to rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, septic shock, sepsis, endotoxic shock, graft versus host disease, wasting, Crohn's disease, ulcerative colitis, multiple sclerosis,

systemic lupus erythematosis, ENL in leprosy, HIV, AIDS, and opportunistic infections in AIDS.

Detailed Description

The compounds of the present invention affect the levels of phosphodiesterases, 5 TNF α and NF κ B and the method involves the regulation of the levels of phosphodiesterases, TNF α and NF κ B through the administration of compounds of the formula:



I

10 in which:

- (a) X is -O- or -(C_nH_{2n})- in which n has a value of 0, 1, 2, or 3, and R¹ is alkyl of one to 10 carbon atoms, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms, or
- (b) X is -CH= and R¹ is alkylidene of up to 10 carbon atoms, monocycloalkylidene of up to 10 carbon atoms, or bicycloalkylidene of up to 10 carbon atoms;

15 R² is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkylidenemethyl, lower alkoxy, or halo;

20 R³ is (i) phenyl, unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 5 carbon atoms, alkyl of up to 10 carbon atoms, cycloalkyl of up to 10 carbon atoms, alkoxy of up to 10 carbon atoms, cycloalkoxy of up to 10 carbon atoms, alkylidenemethyl of up to 10 carbon atoms, cycloalkylidenemethyl of up to 10 carbon atoms, phenyl, or methylenedioxy; (ii) pyridine, substituted pyridine, pyrrolidine, imidazole, naphthalene, or thiophene; (iii) cycloalkyl of 4 - 10 carbon atoms,

25

unsubstituted or substituted with 1 or more substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, phenyl;

5 each of R⁴ and R⁵ taken individually is hydrogen or R⁴ and R⁵ taken together are a carbon-carbon bond;

Y is -COZ, -C≡N, or lower alkyl of 1 to 5 carbon atoms;

Z is -OH, -NR⁶R⁶, -R⁷, or -OR⁷;

10 R⁶ is hydrogen or lower alkyl; and


R⁷ is alkyl or benzyl.

One preferred group are the compounds of Formula I in which R¹ is alkyl, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms; X is -(CH₂)_n- or -O-, where n = 0, 1, 2, or 3; R² is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, halo; and R⁴, R⁵, Y, Z, R⁶, and R⁷ are as therein defined.

A second preferred group of compounds are those of Formula I in which R³ is (i) phenyl or naphthalene, unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, or carbamoyl substituted with alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 5 carbon atoms, alkyl or cycloalkyl of 1 to 10 carbon atoms, alkoxy or cycloalkoxy of 1 to 10 carbon atoms; or (ii) cycloalkyl of 4 to 10 carbon atoms, 20 unsubstituted or substituted with one or more substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or phenyl.

- 8 -


Particularly preferred nitriles are compound of the formula:



IIA.

5

or



IIB

wherein:

(a) X is -O- or -(C_nH_{2n}) - in which n has a value of 0, 1, 2, or 3, and R¹ is alkyl of up to 10 carbon atoms, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms, or

10 (b) X is -CH=, and R¹ is alkylidene of up to 10 carbon atoms or monocycloalkylidene of up to 10 carbon atoms;

R² is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, or halo; and


15 R³ is (i) phenyl or naphthyl, unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, or carbamoyl substituted with alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 5 carbon atoms, alkoxy or cycloalkoxy of 1 to 10 carbon atoms; or (ii) cycloalkyl of 4 to 10 carbon atoms, unsubstituted or substituted with one or more substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or phenyl.

20

25

- 9 -


Particularly preferred alkanoic acid derivatives are compound of the formula:



IIIA.

5

or



IIIB

wherein:

(a) X is -O- or -(C_nH_{2n})- in which n has a value of 0, 1, 2, or 3, and R¹ is alkyl of up to 10 carbon atoms, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms, or

(b) X is -CH=, and R¹ is alkylidene of up to 10 carbon atoms or monocycloalkylidene of up to 10 carbon atoms;

R² is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, or halo;

R³ is (i) phenyl or naphthyl, unsubstituted or substituted with one or more substituents each selected independently from nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, or carbamoyl substituted with alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 5 carbon atoms, alkyl or cycloalkyl of 1 to 10 carbon atoms, alkoxy or cycloalkoxy of 1 to 10 carbon atoms; or (ii) cycloalkyl of 4 to 10 carbon atoms, unsubstituted or substituted with one or more substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino,

- 10 -

substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or phenyl; and


Z is -OH, -NR⁶R⁶, R⁷, or -OR⁷ in which R⁶ is hydrogen or lower alkyl; and R⁷ is alkyl or benzyl.

5 The term alkyl as used herein denotes a univalent saturated branched or straight hydrocarbon chain. Unless otherwise stated, such chains can contain from 1 to 18 carbon atoms. Representative of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, 10 hexadecyl, heptadecyl, octadecyl, and the like. When qualified by "lower", the alkyl group will contain from 1 to 6 carbon atoms. The same carbon content applies to the parent term "alkane" and to derivative terms such as "alkoxy".

15 The term cycloalkyl as used herein denotes a univalent saturated cyclic hydrocarbon chain. Unless otherwise stated, such chains can contain up to 18 carbon atoms. Monocyclicalkyl refers to groups having a single ring group. Polycycloalkyl denotes hydrocarbon systems containing two or more ring systems with two or more ring carbon atoms in common. Benzocycloalkyl signifies a monocyclicalkyl group fused to a benzo group. Representative of monocycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, 20 cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentadecyl, cyclohexadecyl, cycloheptadecyl, and cyclooctadecyl. Representative of polycycloalkyl include bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, and bicyclo[2.2.2]octyl. Benzocycloalkyl is typified by tetrahydronaphthyl, indanyl, and 1,2-benzocycloheptanyl.

25 The compounds can be prepared using methods which are known in general for the preparation of diaryl alkenes. For example, an appropriately substituted *bis*(aryl) ketone can be treated with a dialkyl cyanomethylphosphonate to yield the corresponding *bis* aryl acrylonitrile. This can be hydrolysed to the corresponding carboxylic acid, esters and amides by methods known *per se*. Alternatively, the substituted *bis*(aryl) ketone 30 can be treated with an alkyl disubstituted phosphonoacetate or a disubstituted carbamoylmethylphosphonate and lithium hexamethyldisilazide to form the ester or amide, respectively, directly. The substituted *bis*(aryl) ketone alternatively can be treated with the appropriate triphenylphosphite.

- 11 -



The *bis*(aryl) ketones also are obtained by methods known *per se* such as for example by Friedel-Crafts acylations with acid chlorides in the presence of a Lewis acid.

Representative examples of these compounds include 3,3-*bis*-(3,4-dimethoxyphenyl)acrylonitrile, 3,3-*bis*-(3-ethoxy-4-methoxyphenyl)acrylonitrile, methyl 3,3-*bis*-(3-ethoxy-4-methoxyphenyl)-propenoate, methyl 3-(3-ethoxy-4-methoxyphenyl)-3-phenylpropenoate, 3-(3-propoxy-4-methoxyphenyl)-3-phenylacrylonitrile, 3-(3-ethoxy-4-methoxyphenyl)-3-phenylacrylonitrile, 3,3-*bis*-(3-cyclopentoxy-4-methoxyphenyl)acrylonitrile, methyl 3-(3-cyclopentoxy-4-methoxyphenyl)-3-phenylpropenoate, 3-(3-cyclopentoxy-4-methoxyphenyl)-3-phenylacrylonitrile, 3-(3-cyclopentoxy-4-methoxyphenyl)-3-phenylpropene, 1-(3-cyclopentoxy-4-methoxyphenyl)-1-phenylpropane, 3-(3-cyclopentoxy-4-methoxyphenyl)-3-phenylpropanenitrile, methyl 3-(3-cyclopentoxy-4-methoxyphenyl)-3-phenylpropanoate, 3-(3-ethoxy-4-methoxyphenyl)-3-phenylpropanenitrile, methyl 3-(3-ethoxy-4-methoxyphenyl)-3-phenylpropanoate, 3,3-*bis*-(3,4-dimethoxyphenyl)propanenitrile, 3,3-*bis*-(3-ethoxy-4-methoxyphenyl)propanenitrile, 3-(3,4-dimethoxyphenyl)-3-phenylacrylonitrile, 3-(3-ethoxy-4-methoxyphenyl)-3-naphthylpropanenitrile, 3-(3,4-dimethoxyphenyl)-3-phenylpropanenitrile and 3-(3,4-dimethoxyphenyl)-3-(3-ethoxy-4-methoxyphenyl)propanenitrile.

A further group of preferred compounds include 4,4-*bis*-(3,4-dimethoxyphenyl)-but-3-en-2-one; 4-(3,4-dimethoxyphenyl)-4-(3-ethoxy-4-methoxyphenyl)but-3-en-2-one; 4-(3,4-dimethoxyphenyl)-4-phenylbut-3-en-2-one; 4-(3,4-dimethoxyphenyl)-4-(3-cyclopentoxy-4-methoxyphenyl)but-3-en-2-one; 4-(3,4-dimethoxyphenyl)-4-(3-indan-2-yloxy-4-methoxyphenyl)but-3-en-2-one; 4-(3-ethoxy-4-methoxyphenyl)-4-(4-pyridyl)but-3-en-2-one; 4-(3-ethoxy-4-methoxyphenyl)-4-(4-pyridyl)butan-2-one; 4-(3-cyclopentoxy-4-methoxyphenyl)-4-(4-pyridyl)but-3-en-2-one; 4-(3-cyclopentoxy-4-methoxyphenyl)-4-(4-pyridyl)butan-2-one; methyl 3-(3-cyclopentoxy-4-methoxyphenyl)-3-(4-pyridyl)prop-2-enoate; methyl 3-(3-ethoxy-4-methoxyphenyl)-3-(4-pyridyl)prop-2-enoate; methyl 3-(3-ethoxy-4-methoxyphenyl)-3-(4-pyridyl)propanoate; 4-(3-ethoxy-4-methoxyphenyl)-4-(2-furyl)but-3-en-2-one; 3-(3-ethoxy-4-meth-

oxyphenyl)-3-(2-furyl)prop-2-enenitrile; 3-(3-ethoxy-4-methoxyphenyl)-3-(4-pyridyl)prop-2-enenitrile; 3-(3-ethoxy-4-methoxyphenyl)-3-(4-pyridyl)propanenitrile; 3-(3-cyclopentoxy-4-methoxyphenyl)-3-(4-pyridyl)prop-2-enenitrile; 3-(3-cyclopentoxy-4-methoxyphenyl)-3-(4-pyridyl)propanenitrile; 4-(3,4-dimethoxyphenyl)-4-(4-methoxy-3-prop-1-enylphenyl)but-3-en-2-one; 4-(3,4-dimethoxyphenyl)-4-(4-methoxy-3-prop-1-enylphenyl)but-3-en-2-one; 4,4-*bis*-(3,4-dimethoxyphenyl)butan-2-one; 4-(3,4-dimethoxyphenyl)-4-(3-ethoxy-4-methoxyphenyl)butan-2-one; 4-(3,4-dimethoxyphenyl)-4-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)butan-2-one; 4-(3,4-dimethoxyphenyl)-4-(4-methoxy-3-prop-1-enylphenyl)butan-2-one; 4,4-*bis*-(3-ethoxy-4-methoxyphenyl)but-3-en-2-one; 3-(3,4-dimethoxyphenyl)-3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)prop-2-enenitrile; 3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)-3-phenyl-prop-2-enenitrile; 1-(3,4-dimethoxyphenyl)-1-(3-ethoxy-4-methoxyphenyl)pentan-3-one; 1-(3,4-dimethoxyphenyl)-1-(3-ethoxy-4-methoxyphenyl)pent-1-en-3-one; 1,1-*bis*-(3,4-dimethoxyphenyl)pentan-3-one; 3-(3,4-dimethoxyphenyl)-3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)prop-2-enenitrile; 3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)-3-phenyl-propanenitrile; 3,3-*bis*-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)propanenitrile; 3,3-*bis*-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)prop-2-enenitrile; 3-(3,4-dimethoxyphenyl)-3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)prop-2-enamide; 3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl-3-phenyl)propanamide; 3,3-*bis*-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)propanamide; 3,3-*bis*-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)prop-2-enamide; 3-(3,4-dimethoxyphenyl)-3-(3-ethoxy-4-methoxyphenyl)prop-2-enamide; 3,3-*bis*-(3-ethoxy-4-methoxyphenyl)prop-2-enamide; 3,3-*bis*-(3,4-dimethoxyphenyl)prop-2-enamide; 3,3-*bis*-(3-ethoxy-4-methoxyphenyl)propanamide; 3,3-*bis*-(3,4-dimethoxyphenyl)propanamide; 4-(3,4-dimethoxyphenyl)-4-(4-methoxy-3-exo-norbornyloxyphenyl)but-3-en-2-one; 3-(3,4-dimethoxyphenyl)-3-(4-methoxy-3-exo-norbornyloxyphenyl)prop-2-enenitrile; 3-(3,4-dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)prop-2-enenitrile; 3-(4-aminophenyl)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile; and 3-(4-aminophenyl)-3-(3-ethoxy-4-dimethoxyphenyl)prop-2-enenitrile.

These compounds may possess one or more centers of chirality and thus can exist as optical isomers. Both the racemates of these isomers and the individual isomers themselves, as well as diastereoisomers when there are two or more chiral centers, are within the scope of the present invention. The racemates can be used as such or can be

separated into their individual isomers mechanically as by chromatography using a chiral absorbent. Alternatively, the individual isomers can be prepared in chiral form or separated chemically from a mixture by forming salts with a chiral acid, such as the individual enantiomers of 10-camphorsulfonic acid, camphoric acid, alpha-bromocamphoric acid, methoxyacetic acid, tartaric acid, diacetyltauric acid, malic acid, pyrrolidone-5-carboxylic acid, and the like, and then freeing one or both of the resolved bases, optionally repeating the process, so as to obtain either or both isomers substantially free of the other; *i.e.*, in a form having an optical purity of >95%. In addition, the compounds in which R⁴ and R⁵ taken together are a carbon-carbon bond can exist as cis (Z) and trans (E) isomers.

The compounds can be used, under the supervision of qualified professionals, to inhibit the undesirable effects of TNF α , NF κ B, and phosphodiesterase. The compounds can be administered orally, rectally, or parenterally, alone or in combination with other therapeutic agents including antibiotics, steroids, *etc.*, to a mammal in need of treatment.

Oral dosage forms include tablets, capsules, dragees, and similar shaped, compressed pharmaceutical forms. Isotonic saline solutions containing 20-100 milligrams/milliliter can be used for parenteral administration which includes intramuscular, intrathecal, intravenous and intra-arterial routes of administration. Rectal administration can be effected through the use of suppositories formulated from conventional carriers such as cocoa butter.

Dosage regimens must be titrated to the particular indication, the age, weight, and general physical condition of the patient, and the response desired but generally doses will be from about 1 to about 1000 milligrams/day as needed in single or multiple daily administration. In general, an initial treatment regimen can be copied from that known to be effective in interfering with TNF α activity for other TNF α mediated disease states by the compounds of the present invention. Treated individuals will be regularly checked for T cell numbers and T4/T8 ratios and/or measures of viremia such as levels of reverse transcriptase or viral proteins, and/or for progression of cytokine-mediated disease associated problems such as cachexia or muscle degeneration. If no effect is observed following the normal treatment regimen, then the amount of cytokine activity interfering agent administered is increased, *e.g.*, by fifty percent a week.

The compounds of the present invention can also be used topically in the treatment or prophylaxis of topical disease states mediated or exacerbated by excessive TNF α

production, such as viral infections, for example those caused by the herpes viruses or viral conjunctivitis, psoriasis, other skin disorders and diseases, *etc.*

The compounds can also be used in the veterinary treatment of mammals other than humans in need of prevention or inhibition of TNF α production. TNF α mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples include 5 feline immunodeficiency virus, equine infectious anaemia virus, caprine arthritis virus, visna virus, and maedi virus, as well as other lentiviruses.

Inhibition of PDE III, PDE IV, TNF α and NF κ B by these compounds can be 10 conveniently assayed using methods known in the art, e.g., enzyme immunoassay, radioimmunoassay, immunoelectrophoresis, affinity labeling, *etc.*, of which the following are typical.

Enzyme-linked Immunosorbent Assay for TNF α

PBMC isolation: PBMC from normal donors were obtained by Ficoll-Hypaque 15 density centrifugation. Cells were cultured in RPMI supplemented with 10% AB+ serum, 2mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin.

PBMC suspensions: Drugs were dissolved in dimethylsulfoxide (Sigma Chemical), further dilutions were done in supplemented RPMI. The final 20 dimethylsulfoxide concentration in the presence or absence of drug in the PBMC suspensions was 0.25 wt %. Drugs were assayed at half-log dilutions starting at 50 mg/mL. Drugs were added to PBMC (10^6 cells/mL) in 96 wells plates one hour before the addition of LPS.

Cell stimulation: PBMC (10^6 cells/mL) in the presence or absence of drug were stimulated by treatment with 1 mg/mL of LPS from *Salmonella minnesota* R595 (List 25 Biological Labs, Campbell, CA). Cells were then incubated at 37°C for 18-20 hours. Supernatants were then harvested and assayed immediately for TNF α levels or kept frozen at -70°C (for not more than 4 days) until assayed.

TNF α Determination: The concentration of TNF α in the supernatant was determined by human TNF α ELISA kits (ENDOGEN, Boston, MA) according to the 30 manufacturer's directions.

Phosphodiesterase can be determined in conventional models. For example, using the method of Hill and Mitchell, U937 cells of the human promonocytic cell line are grown to 1×10^6 cells /mL and collected by centrifugation. A cell pellet of 1×10^9 cells is washed in phosphate buffered saline and then frozen at -70°C for later purification

5 or immediately lysed in cold homogenization buffer (20mM Tris-HCl, pH 7.1, 3 mM 2-mercaptoethanol, 1 mM magnesium chloride, 0.1 mM ethylene glycol-bis-(β -aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 1 μM phenylmethylsulfonyl fluoride (PMSF), and 1 $\mu\text{g}/\text{mL}$ leupeptin). Cells are homogenized with 20 strokes in a Dounce homogenizer and supernatant containing the cytosolic fraction are obtained

10 by centrifugation. The supernatant then is loaded onto a Sephadryl S-200 column equilibrated in homogenization buffer. Phosphodiesterase is eluted in homogenization buffer at a rate of approximately 0.5 mL/min and fractions are assayed for phosphodiesterase activity $-/+$ rolipram. Fractions containing phosphodiesterase activity(rolipram sensitive) are pooled and aliquoted for later use.

15 The phosphodiesterase assay is carried out based on procedure described by Hill and Mitchell. The assay is carried out in a total volume of 100 μl containing various concentration of test compounds, 50mM Tris-HCl, pH 7.5,5 mM magnesium chloride and 1 μM cAMP of which 1% was ^3H cAMP. Reactions are incubated at 30°C for 30 minutes and terminated by boiling for 2 minutes. The amount of phosphodiesterase IV

20 containing extract used for these experiments is predetermined such that reactions are within the linear range and consumed less than 15% of the total substrate. Following termination of reaction, samples are chilled at 4°C and then treated with 10 μl 10 mg/mL snake venom for 15 min at 30°C . Unused substrate then is removed by adding 200 μl of a quaternary ammonium ion exchange resin (AG1-X8, BioRad) for 15

25 minutes. Samples then are spun at 3000 rpm, 5 min and 50 μl of the aqueous phase are taken for counting. Each data point is carried out in duplicate and activity is expressed as percentage of control. The IC_{50} of the compound then is determined from dose response curves of a minimum of three independent experiments.

30 The following examples will serve to further typify the nature of this invention but should not be construed as a limitation in the scope thereof, which scope is defined solely by the appended claims.

EXAMPLE 1**3,3-bis-(3,4-Dimethoxyphenyl)acrylonitrile****A. 3,4, 3',4'-Tetramethoxybenzophenone**

To a stirred ice bath cooled solution of veratrole (2.07 g, 15.0 mmol) in 30 mL of 5 methylene chloride under nitrogen was added aluminum chloride (2.20 g, 16.5 mmol). A slight exotherm resulted. To the reaction mixture was then added 3,4-dimethoxybenzoyl chloride (3.01 g, 15.0 mmol) and 20 mL of methylene chloride. The reaction was then allowed to warm to room temperature and then refluxed for 3.5 hours and then allowed to stir at room temperature for 16 hours. The reaction mixture was 10 then poured into 50 mL of ice water and stirred for 15 minutes. This mixture was extracted with methylene chloride (2 x 25 mL each). The combined extracts were dried over sodium sulfate and concentrated *in vacuo* to afford the crude product as a tan solid.

The crude product was purified by flash chromatography (silica gel, 4/96 ethyl acetate/methylene chloride) to afford 2.97 g (66%) of the product as a white powder: ¹H NMR (CDCl₃) δ 7.4 (m, 4 H), 6.91 (m, 2 H), 3.97 (s, 6 H), 3.95 (s, 6 H); ¹³C NMR (DMSO-d₆) δ 194.4, 152.5, 148.8, 130.7, 124.7, 112.2, 109.7, 56.0. Anal. Calcd for C₁₇H₁₈O₅. Theoretical: C, 67.54; H, 6.00. Found: C, 67.42; H, 6.03.

B. 3,3-bis-(3',4'-Dimethoxyphenyl)acrylonitrile

To an ice bath cooled stirred suspension of sodium hydride (5.0 mmol) in 20 mL 20 of tetrahydrofuran was added 0.8 mL of diethyl cyanomethylphosphonate dropwise via syringe. The mixture was allowed to warm to room temperature and then 3,4,3',4'-tetramethoxybenzophenone (1.51 g, 5.00 mmol) and 10 mL of tetrahydrofuran were added. The mixture was stirred for 5 days and then quenched with 25 100 mL of H₂O. The reaction mixture was then extracted with methylene chloride (50 mL and 25 mL). The combined extracts were dried over sodium sulfate and concentrated to afford the crude product as an oil. The crude product was purified by flash chromatography to afford the product as a white wax: ¹H NMR (CDCl₃) δ 7.95 (br m, 6 H), 5.57 (s, 1 H), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.87 (s, 3 H), 3.84 (s, 3 H); ¹³C NMR (DMSO-d₆) δ 162.4, 151.0, 150.5, 148.8, 148.5, 131.8, 129.5, 123.2, 122.2, 30 118.6, 112.7, 111.4, 110.7, 110.7, 91.9, 56.0, 55.9, 55.9.

EXAMPLE 2**cis and trans 3-(3, 4-Dimethoxyphenyl)-3-(3-ethoxy-4-methoxyphenyl)acrylonitrile****A. 3, 4-Dimethoxy-3-ethoxy-4-methoxybenzophenone**

5 To an ice bath cooled stirred suspension of 3-ethoxy-4-methoxybenzoic acid (0.98 g, 5.0 mmol) in 20 mLmethylene chloride was added oxalyl chloride (0.44 mL, 5.0 mmol) and 2 drops of N,N dimethylformamide (dimethylformamide). The resulting yellow mixture was stirred at room temperature for 35 minutes at which time a solution had formed. The solution was cooled in an ice bath and veratrole (0.64 mL, 10 5.0 mmol) was added followed by aluminum chloride (0.73 g, 5.5 mmol). The ice bath was removed and the mixture was stirred at room temperature. The reaction was monitored by HPLC (Waters Nova-Pak/C₈ column 3.9 x 150 mm, 4 micron, 1mL/min, 35/65 acrylonitrile/0.1% aqueous phosphoric acid and after 37 hours the reaction was complete. The reaction mixture was poured into 30 mL of ice, stirred for 15 30 minutes and was then extracted with methylene chloride (3 x 20 mL). The methylene chloride extracts were washed successively with aqueous sodium bicarbonate (30 mL), water (2 x 50 mL) and brine (50 mL). The organic layer was then dried over magnesium sulfate, filtered and concentrated *in vacuo* to afford 1.05 g of a brown solid. The crude product was purified by flash column chromatography 20 (silica gel, 5% ethyl acetate/methylene chloride) and the resulting product was then dried *in vacuo* (60 °C, < 1mmHg) to afford 0.8 g (51%) of the product: mp 122-124.5 °C; ¹H NMR (CDCl₃) δ 7.48-7.34 (m, 4 H), 6.98-6.86 (m, 2 H), 4.16 (q, J = 7 Hz, 2 H), 3.96 (s, 3 H), 3.96 (s, 3 H), 3.94 (s, 3 H), 1.49 (t, J = 7 Hz, 3 H); ¹³C NMR (CDCl₃) δ 194.4, 152.8, 152.5, 148.8, 148.0, 130.7, 130.6, 124.6, 124.5, 113.5, 25 112.2, 109.9, 109.7, 64.3, 55.9, 55.9, 14.6; HPLC (Waters Nova-Pak/C₈ column, 3.9 x 150 mm, 4 micron, 1 mL/min, 35/65 acrylonitrile/0.1% aqueous phosphoric acid 8 min, 99%; Anal. Calcd for C₁₈H₂₀O₅. Theoretical: C, 68.34; H, 6.37. Found: C, 68.56; H, 6.51.

B. cis and trans 3-(3, 4-Dimethoxyphenyl)-3-(3-ethoxy-4-methoxyphenyl)acrylonitrile

To an ice bath cooled stirred solution of diethylcyanomethylphosphonate (0.9 mL, 5.5 mmol) in 15 mL of tetrahydrofuran was added a 1.3 M solution of lithium

hexamethyldisilazide (4.2 nL, 5.5 mmol) in tetrahydrofuran. The solution was allowed to warm to room temperature and was stirred for 30 minutes and then a slurry of 3, 4-dimethoxy-3-ethoxy-4-methoxybenzophenone (1.58 g, 5.00 mmol) in 20 mL of tetrahydrofuran was added. The reaction mixture was stirred at room temperature for 21 hours and was then quenched with 100 mL of water. The resulting mixture was extracted with methylene chloride (2 x 50 mL). The combined extracts were washed with water, dried over magnesium sulfate, and concentrated *in vacuo* to afford the crude product as an orange oil. The crude product was purified by flash column chromatography (silica gel, 3% ethyl acetate/methylene chloride) and then recrystallized from hexane/ethyl. The resulting product was then dried *in vacuo* (40 °C, < 1 mmHg) to afford 0.6 g (35 %) of a white solid: mp 103-106 °C; ¹H NMR (CDCl₃) δ 7.10-6.75 (m, 6 H), 5.55 (s, 1H), 4.17-3.76 (m, 1 1 H), 1.54-1.36 (m, 3 H); ¹³C NMR (CDCl₃) δ 162.5, 151.0, 150.8, 150.5, 148.8, 148.6, 148.1, 147.8, 131.9, 131.7, 129.6, 129.5, 123.2, 123.1, 122.1, 122.0, 118.6, 114.2, 112.9, 112.8, 111.4, 110.9, 110.9, 110.7, 110.7, 91.8, 64.5, 56.0, 5 5.9, 14.6; HPLC (Waters Nova-Pak/C₈ column, 3.9 x 150 mm, 4 micron, 1 mL/min, 45/55 acrylonitrile/0.1% aqueous phosphoric acid 7 min, 100%; Anal. Calcd for C₂₀H₂₁NO₄. Theoretical: C, 70.78; H, 6.24; N, 4.13. Found: C, 70.62; H, 6.2 1; N, 4.07.

20

EXAMPLE 3**3-(3,4-Dimethoxyphenyl)-3-phenylacetate****A. 3,4-Dimethoxybenzophenone**

3,4-Dimethoxybenzophenone was prepared analogously to 3,4,3',4'-tetramethoxybenzophenone using veratrole (2 mL, 15 mmol), aluminum chloride (2.2 g, 16.5 mmol) and benzoyl chloride (1.8 mL, 15.5 mmol). The crude mixture was purified by flash column chromatography (silica gel, 3% ethyl acetate/methylene chloride) to yield 3.44 g (93%) of the product as a white solid: mp 99-100 °C; ¹H NMR (CDCl₃) δ 7.82-7.30 (m, 7 H), 6.95-6.85 (m, 1 H), 3.96 (s, 3 H), 3.94 (s, 3 H); ¹³C NMR (CDCl₃) δ 195.5, 153.0, 149.0, 138.2, 131.8, 130.2, 129.6, 128.1, 125.4, 112.1, 109.7, 56.0, 56.0; Anal. Calcd for C₁₅H₁₄O₃. Theoretical: C, 74.36; H, 5.82. Found: C, 74.21; H, 6.01.

B. 3-(3,4-Dimethoxyphenyl)-3-phenylacetate (E and Z Isomers)

3-(3,4-Dimethoxyphenyl)-3-phenylacetate was prepared analogously to 3,3-*bis*-(3,4-dimethoxyphenyl)acrylate using 3,4-dimethoxybenzophenone (4.8 g, 20 mmol), trimethylphosphonoacetate (4.1 g, 22 mmol) and lithium hexamethyldisilazide (22 mL, 22 mmol, 1M) with a reaction time of 138 hours at reflux. The crude mixture was purified by flash column chromatography (silica gel, 1% ethyl acetate/methylene chloride) to afford 14.39 g (73%) of a mixture of the E and Z isomers as an oil. The isomers were separated by additional purification (silica gel, 1% ethyl acetate/methylene chloride) to afford pure samples of each of the isomers.

10 Isomer 1: ^1H NMR (CDCl_3) δ 7.40-7.36 (m, 3 H), 7.26-7.20 (m, 2 H), 6.88 (s, 1 H), 6.80 (s, 2 H), 6.30 (s, 1 H), 3.88 (s, 3 H), 3.82 (s, 3 H), 3.60 (s, 3 H); ^{13}C NMR (CDCl_3) δ 166.5, 156.9, 150.4, 148.7, 138.9, 133.4, 129.1, 128.1, 128.0, 127.8, 122.1, 114.9, 110.8, 110.6, 55.9, 55.8, 51.1; Anal. Calcd for $\text{C}_{18}\text{H}_{18}\text{O}_4$. Theoretical: C, 72.47; H, 6.08. Found: C, 72.08; H, 6.11.

15 Isomer 2: ^1H NMR (CDCl_3) δ 7.35-7.32 (m, 5 H), 6.90-6.83 (m, 2 H), 6.73 (s, 1 H), 6.30 (s, 1 H), 3.92 (s, 3 H), 3.81 (s, 3 H), 3.64 (s, 3 H); ^{13}C NMR (CDCl_3) δ 166.6, 156.7, 149.2, 148.3, 141.2, 131.1, 129.4, 128.5, 128.3, 122.4, 116.4, 112.7, 110.4, 55.8, 55.7, 51.2; Anal. Calcd for $\text{C}_{18}\text{H}_{18}\text{O}_4$. Theoretical: C, 72.47; H, 6.08. Found: C, 72.28; H, 5.94.

20

EXAMPLE 4**3-Phenyl-3-(3'-ethoxy-4-methoxyphenyl)acrylamide (E and Z Isomers)**

The acrylamide was prepared analogously to 3,3-*bis*-(3,4-dimethoxyphenyl)acrylate using 3-ethoxy-4-methoxybenzophenone (0.3 g, 1.2 mmol), diethylcarbamoylmethylphosphonate (0.25 g, 1.3 mmol) and lithium hexamethyldisilazide (1 mL, 1.3 mmol, 1.3M) with a reaction time of 54 hours at reflux. The crude mixture was purified by flash column chromatography (silica gel, 45% ethyl acetate/methylene chloride) to afford 0.06 g (17%) of a mixture of the E and Z isomers as an oil: ^1H NMR (CDCl_3) δ 7.54-7.19 (m, 10 H), 7.00-6.65 (m, 6 H), 6.34 (s, 2 H), 5.54 (s, 1 H), 5.55 (s, 1 H), 5.24 (s, 1 H), 5.04 (s, 1 H), 4.16 (m, 4 H), 3.92 (s, 3 H), 3.87 (s, 3 H), 1.60-1.33 (m, 6 H); ^{13}C NMR (CDCl_3) δ 168.7, 168.6, 150.8, 150.4, 149.7, 148.4, 148.0, 140.7, 138.2, 133.0, 130.2, 129.2, 129.1, 128.8, 128.3, 128.0, 121.9, 121.6, 120.0, 113.7, 111.9, 111.4, 110.8, 64.4, 64.3, 55.9, 14.6;

- 20 -

Anal. Calcd for $C_{18}H_{19}NO_3 \cdot 0.35H_2O$. Theoretical: C, 71.19; H, 6.54; N, 4.61. Found: C, 71.19; H, 6.68; N, 4.45.

EXAMPLE 5

1-(3,4-Dimethoxyphenyl)-1-phenylprop-1-ene (E and Z Isomers)

5 1-(3,4-Dimethoxyphenyl)-1-phenylprop-1-ene was prepared analogously to methyl 3,3-*bis*-(3,4-dimethoxyphenyl)acrylate using 3,4-dimethoxybenzophenone (3 g, 12.4 mmol), (ethyl)triphenylphosphonium bromide (5.1 g, 13.6 mmol) and lithium hexamethyldisilazide (13.6 mL, 13.6 mmol, 1M) with a reaction time of 4 hours at room temperature. The crude mixture was purified by flash column chromatography 10 (silica gel, 10% hexane/methylene chloride) to afford 1.3 g (41%) of a mixture of the E and Z isomers as a white solid: mp 72-73°C; 1H NMR ($CDCl_3$) δ 7.40-6.80 (m, 16 H), 6.16-6.08 (m, 2 H), 3.90-3.80 (m, 12 H), 1.97-1.73 (m, 6 H); ^{13}C NMR ($CDCl_3$) δ 148.6, 148.5, 148.1, 147.8, 142.9, 142.3, 142.0, 140.0, 136.0, 132.5, 129.9, 128.0, 128.0, 127.1, 126.7, 126.6, 123.8, 122.6, 122.5, 119.8, 113.6, 110.8, 110.7, 110.4, 15 55.8, 55.8, 55.7, 15.7, 15.5; Anal. Calcd for $C_{17}H_{18}O_2$. Theoretical: C, 80.28; H, 7.13. Found: C, 79.94; H, 7.12.

EXAMPLE 6

1-(3,4-Dimethoxyphenyl)-1-(3-ethoxy-4-methoxyphenyl)prop-1-ene (E and Z Isomers)

20 1-(3,4-Dimethoxyphenyl)-1-(3-ethoxy-4-methoxyphenyl)prop-1-ene was prepared analogously to methyl 3,3-*bis*-(3,4-dimethoxyphenyl)acrylate using 3,4-dimethoxy-3'-ethoxy-4'-methoxybenzophenone (1.6 g, 5 mmol), (ethyl)triphenylphosphonium bromide (2.04 g, 5.5 mmol) and lithium hexamethyldisilazide (4.2 mL, 5.5 mmol, 1.3M) with a reaction time of 24 hours at room temperature. The crude mixture was purified by flash column chromatography 25 (silica gel, 10% hexane/methylene chloride) to afford 0.8 g (49%) of a mixture of the E and Z isomers as a white solid: mp 65.5-68°C; 1H NMR ($CDCl_3$) δ 6.95-6.65 (m, 12 H), 6.14-6.00 (m, 2 H), 4.11-3.78 (m, 22 H), 1.86-1.74 (m, 6 H), 1.50-1.36 (m, 6 H); ^{13}C NMR ($CDCl_3$) δ 148.5, 148.4, 148.1, 147.7, 141.8, 141.7, 136.1, 136.0, 132.6, 30 132.5, 122.5, 122.3, 119.7, 114.7, 113.1, 111.9, 111.0, 110.7, 110.4, 55.9, 55.8, 55.8,

55.7, 15.7, 14.7; Anal. Calcd for $C_{20}H_{24}O_4$. Theoretical: C, 73.15; H, 7.37. Found: C, 73.33; H, 7.39.

EXAMPLE 7

1-(3,4-Dimethoxyphenyl)-1-(3-ethoxy-4-methoxyphenyl)but-1-ene (E and Z Isomers)

5 1-(3,4-Dimethoxyphenyl)-1-(3-ethoxy-4-methoxyphenyl)but-1-ene was prepared analogously to methyl 3,3-bis-(3,4-dimethoxyphenyl)acrylate using 3,4-dimethoxy-3'-ethoxy-4'-methoxybenzophenone (1 g, 3.2 mmol), propyltriphenylphosphonium bromide (1.34 g, 3.5 mmol) and lithium hexamethyldisilazide (2.7 mL, 3.5 mmol, 10 1.3M) with a reaction time of 2.5 hours at room temperature. The crude mixture was purified by chromatography (silica gel, methylene chloride) followed by a Kugelrohr distillation to yield 0.77 g (71%) of a mixture of the E and Z isomers as an oil: 1H NMR ($CDCl_3$) δ 6.92-6.65 (m, 12 H), 6.02-5.89 (m, 2 H), 4.12-3.96 (m, 4 H), 3.92 (s, 3 H), 3.91 (s, 3 H), 3.86 (s, 3 H), 3.85 (s, 3 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 2.22-2.04 (m, 4 H), 1.51-1.38 (m, 6 H), 1.14-0.98 (m, 6 H); ^{13}C NMR ($CDCl_3$) δ 148.5, 148.1, 147.8, 147.7, 140.4, 140.4, 136.0, 135.9, 133.0, 132.9, 130.1, 130.0, 122.2, 119.8, 114.6, 113.1, 112.0, 111.0, 110.7, 110.4, 64.3, 64.2, 55.9, 23.2, 14.8, 14.7; Anal. Calcd for $C_{21}H_{26}O_4$. Theoretical: C, 73.66; H, 7.65. Found: C, 73.32; H, 7.26.

EXAMPLE 8

3-(3-Ethoxy-4-methoxyphenyl)-3-phenylacrylonitrile (E and Z Isomers)

20 3-(3-Ethoxy-4-methoxyphenyl)-3-phenylacrylonitrile was prepared analogously to 3,3-bis-(3,4-dimethoxyphenyl)acrylate using 3-ethoxy-4-methoxybenzophenone (1.3 g, 5 mmol), diethylcyanomethylphosphonate (0.9 mL, 5.5 mmol) and lithium hexamethyldisilazide (4.2 mL, 5.5 mmol, 1.3M) with a reaction time of 24 hours at 25 room temperature. The crude mixture was purified by flash column chromatography (silica gel, methylene chloride) to afford 1.35 g (96%) of a mixture of the E and Z isomers as a white solid: mp 74-77°C; 1H NMR ($CDCl_3$) δ 7.50-7.24 (m, 10 H), 7.07-6.75 (m, 6 H), 5.67 (s, 1 H), 5.60 (s, 1 H), 4.15-3.95 (m, 4 H), 3.92 (s, 3 H), 3.89 (s, 3 H), 1.50-1.36 (m, 6 H); ^{13}C NMR ($CDCl_3$) δ 162.8, 162.7, 151.4, 150.9, 148.1, 147.1, 30 147.9, 139.3, 137.1, 131.3, 130.2, 129.9, 129.5, 129.3, 128.6, 128.5, 128.4, 123.1, 122.0, 118.3, 118.2, 113.9, 112.5, 110.9, 93.3, 92.9, 64.4, 55.9, 55.9, 14.6; Anal.

- 22 -

Calcd for $C_{18}H_{17}NO_2$. Theoretical: C, 77.40; H, 6.13; N, 5.01. Found: C, 77.14; H, 6.06; N, 4.75.

EXAMPLE 9

3-(3-Ethoxy-4-methoxyphenyl)-3-phenylpropionitrile

5 To a solution of 3-(3-ethoxy-4-methoxyphenyl)-3-phenylacrylonitrile (0.9 g, 3.2 mmol) in a mixture of ethanol and ethyl acetate (20 mL/ 30 mL) was added 0.5 g of 10% palladium on carbon catalyst in portions. The mixture was hydrogenated in a Parr-Shaker apparatus at 55-60 psi of hydrogen for 12 days. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to afford the crude 10 product. The crude product was purified by flash column chromatography (silica gel, 4% hexane/methylene chloride) to afford 0.15 g (15%) of the product as an oil: 1H NMR ($CDCl_3$) δ 7.40-7.16 (m, 5 H); 6.88-6.78 (m, 3 H), 4.32 (t, J = 7.5 Hz, 1 H), 4.03 (q, J = 7 Hz, 2 H), 3.85 (s, 3 H), 3.00 (d, J = 7.5 Hz, 2 H), 1.42 (t, J = 7 Hz, 3 H); ^{13}C NMR ($CDCl_3$) δ 148.7, 148.5, 141.5, 133.7, 128.8, 127.4, 127.3, 119.5, 118.5, 15 112.7, 111.6, 64.4, 55.9, 46.7, 24.5, 14.7; Anal. Calcd for $C_{18}H_{17}NO_2$. Theoretical: C, 76.84; H, 6.81; N, 4.98. Found: C, 76.53; H, 6.92; N, 4.95.

EXAMPLE 10

3-(3,4-Dimethoxyphenyl)-3-(3',5'-dimethoxyphenyl)-acrylonitrile (E and Z Isomers)

20 A. 3,4,3',5'-Tetramethoxybenzophenone

3,4,3',5'-Tetramethoxybenzophenone was prepared analogously to 4-(3,4-dimethoxybenzoyl)pyridine using butyl lithium (9 mL, 22 mmol, 2.5M), 4-bromoveratrole (2.9 mL, 20 mmol) and 3,5-dimethoxybenzonitrile (3.75 g, 23 mmol).

The crude product was purified by flash column chromatography (silica gel, 25 methylene chloride) to afford 1.54 g (26%) of the product: mp 107-110 °C; 1H NMR ($CDCl_3$) δ 7.53-7.39 (m, 2 H), 6.95-6.84 (m, 3 H), 6.70-6.60 (m, 1 H), 3.96 (s, 3 H), 3.95 (s, 3 H), 3.83 (s, 6 H); ^{13}C NMR ($CDCl_3$) δ 195.0, 160.4, 153.0, 148.9, 140.1, 130.0, 125.4, 112.0, 109.7, 107.5, 104.1, 56.0, 55.5; Anal. Calcd for $C_{17}H_{18}O_5$. Theoretical: C, 67.54; H, 6.00. Found: C, 67.38; H, 5.96.

B. 3-(3,4-Dimethoxyphenyl)-3-(3',5'-dimethoxyphenyl)acrylonitrile

3-(3,4-Dimethoxyphenyl)-3-(3',5'-dimethoxyphenyl)acrylonitrile was prepared analogously to methyl 3,3-*bis*-(3,4-dimethoxyphenyl)acrylate using 3,4,3',5'-tetra-methoxybenzophenone (0.7 g, 2.3 mmol), diethylcyanomethylphosphonate (0.42 mL, 5 2.5 mmol) and lithium hexamethyldisilazide (1.9 mL, 2.5 mmol, 1.3M) with a reaction time of 60 hours at room temperature. The crude product was purified by flash chromatography (silica gel, 1% ethyl acetate/methylene chloride) to afford 0.66 g (81%) of a mixture of the E and Z isomers as a white solid: mp 88-90°C; ¹H NMR (CDCl₃) δ 7.10-6.80 (m, 6 H), 6.61-6.40 (m, 6 H), 5.66 (s, 1 H), 5.61 (s, 1 H), 3.94 (s, 10 3 H), 3.91 (s, 3 H), 3.87 (s, 3 H), 3.84 (s, 3 H), 3.80 (s, 3 H), 3.77 (s, 6 H); ¹³C NMR (CDCl₃) δ 162.7, 162.5, 160.7, 160.6, 151.1, 150.6, 148.8, 148.5, 141.3, 138.9, 131.1, 129.2, 123.2, 122.1, 118.2, 118.0, 112.6, 110.9, 110.7, 110.7, 107.6, 107.0, 102.1, 102.0, 93.4, 93.1, 56.0, 55.9, 55.5, 55.4; Anal. Calcd for C₁₉H₁₉NO₄. Theoretical: C, 70.14; H, 5.89; N, 4.30. Found: C, 70.33; H, 5.89; N, 4.03.

15

EXAMPLE 11**3-(3,4-Dimethoxyphenyl)-3-(3'-nitrophenyl)acrylonitrile****A. 3,4-Dimethoxy-3'-nitrobenzophenone**

To a stirred ice bath cooled solution of veratrole (2.55 mL, 20 mmol) in methylene chloride (30 mL) under nitrogen was added aluminum chloride (2.93 g, 22 20 mmol). A slight exotherm resulted. To the resulting mixture was added 3-nitrobenzoyl chloride (3.8 g, 20 mmol) in 30 mL of methylene chloride. The reaction was then allowed to warm to room temperature and followed by heating to refluxed. After 5 hours at reflux the reaction mixture was allowed to cool to room temperature and stirred for 72 hours. The reaction mixture was then poured into 100 mL of iced 25 water and stirred for 20 minutes. This mixture was extracted with CH₂Cl₂ (3 x 60 mL). The organic layer was dried over magnesium sulfate and concentrated in vacuo to afford the crude product as a green solid. The crude product was purified by flash column chromatography (silica gel, CH₂Cl₂) to afford 2.21 g (39%) of the product as a yellow solid: mp 133-135°C; ¹H NMR (CDCl₃) δ 8.64-8.56 (m, 1 H), 8.49-8.39 (m, 1 H), 8.10-8.05 (m, 1 H), 7.76-7.65 (m, 1 H), 7.55-7.47 (m, 1 H), 7.36-7.29 (m, 1 H), 7.00-6.87 (m, 1 H), 3.99 (s, 3 H), 3.97 (s, 3 H); ¹³C NMR (CDCl₃) δ 192.8, 153.8, 149.4, 147.9, 139.7, 135.2, 129.5, 128.9, 126.2, 125.6, 124.4, 11.8, 110.0, 56.2, 56.1;

Anal. Calcd for $C_{15}H_{13}NO_5$. Theoretical: C, 62.72; H, 4.56; N, 4.88. Found: C, 62.74; H, 4.59; N, 4.89.

B. 3-(3,4-Dimethoxyphenyl)-3-(3'-nitrophenyl)acrylonitrile

3-(3,4-Dimethoxyphenyl)-3-(3'-nitrophenyl)acrylonitrile was prepared analogously to methyl 3,3-bis-(3,4-dimethoxyphenyl)acrylate using 3,4-dimethoxy-3'-nitrobenzophenone (1.44 g, 5 mmol), diethylcyanomethylphosphonate (0.91 mL, 5.5 mmol) and lithium hexamethyldisilazide (4.2 mL, 5.5 mmol, 1.3M) with a reaction time of 24 hours at room temperature. The crude product was purified by flash chromatography (silica gel, 3% hexane/methylene chloride) to afford 1.12 g (72%) of a mixture of the E and Z isomers as a yellow solid: mp 117.5-120 °C; 1H NMR ($CDCl_3$) δ 8.40-8.17 (m, 4 H), 7.90-7.55 (m, 4 H), 7.08-6.89 (m, 6 H), 5.84 (s, 1 H), 5.71 (s, 1 H), 3.95 (s, 3 H), 3.92 (s, 3 H), 3.88 (s, 3 H), 3.85 (s, 3 H); ^{13}C NMR ($CDCl_3$) δ 160.2, 160.1, 151.7, 151.1, 149.2, 148.3, 148.2, 141.0, 138.8, 135.4, 134.4, 129.9, 129.7, 129.7, 128.1, 124.8, 124.6, 124.4, 123.3, 123.1, 122.3, 117.4, 117.3, 112.3, 111.0, 110.4, 95.7, 94.8, 56.0, 55.9; Anal. Calcd for $C_{17}H_{14}N_2O_4$. Theoretical: C, 65.80; H, 4.55; N, 9.03. Found: C, 65.57; H, 4.64; N, 8.92.

EXAMPLE 12

3-(3'-Aminophenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile (E and Z Isomers)

To a solution of 3-(3,4-dimethoxyphenyl)-3-(3'-nitrophenyl)acrylonitrile (0.7 g, 2.3 mmol) in 40 mL of ethyl acetate was added 0.1 g of 10% palladium on carbon catalyst. The mixture was hydrogenated in a Parr-Shaker apparatus at 55-60 psi of hydrogen for 2.5 hours. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to afford the crude product. The crude product was purified by flash column chromatography (silica gel, 15% ethyl acetate/methylene chloride) to afford 0.25 g (56%) of a mixture of the E and Z isomers as a yellow solid: mp 100-101 °C; 1H NMR ($CDCl_3$) δ 7.30-6.59 (m, 14 H); 5.63 (s, 1 H), 5.59 (s, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.87 (s, 3 H), 3.84 (s, 3 H); ^{13}C NMR ($CDCl_3$) δ 163.1, 162.9, 151.1, 150.5, 148.8, 148.7, 146.5, 146.4, 140.4, 138.2, 131.5, 129.5, 129.5, 129.4, 123.2, 122.1, 119.9, 119.0, 118.4, 118.2, 116.8, 116.6, 115.9, 115.0, 112.7, 111.0, 110.7, 93.3, 92.7, 56.1, 56.0, 55.9; Anal. Calcd for $C_{17}H_{16}N_2O_3$. Theoretical: C, 72.84; H, 5.75; N, 9.99. Found: C, 72.48; H, 6.05; N, 9.58.

- 25 -

EXAMPLE 13

3,4-Dimethoxy-3'-aminobenzophenone

To a solution of 3,4-dimethoxy-3'-nitrobenzophenone (0.5 g, 1.7 mmol) in 40 mL of ethyl acetate was added 0.05 g of 10% palladium on carbon catalyst. The mixture 5 was hydrogenated in a Parr-Shaker apparatus at 55-60 psi of hydrogen for 1.5 hours. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to afford the crude product. The crude product was purified by flash column chromatography (silica gel, 10% ethyl acetate/methylene chloride) to afford 0.17 g (38%) of the product as a yellow solid: mp 157-175 °C; ¹H NMR (CDCl₃) δ 7.56-6.80 10 (m, 7 H); 3.95 (s, 3 H), 3.94 (s, 3 H); ¹³C NMR (CDCl₃) δ 195.7, 152.9, 148.9, 146.4, 139.3, 130.3, 128.9, 125.4, 120.1, 118.4, 115.6, 112.1, 109.7, 56.0, 56.0; Anal. Calcd for C₁₅H₁₅NO₃. Theoretical: C, 70.02; H, 5.88; N, 5.44. Found: C, 70.00; H, 6.10; N, 5.13.

EXAMPLE 14

15. **3-(3,4-Dimethoxyphenyl)-3-(4-nitrophenyl)acrylonitrile (E and Z Isomers)**

A. 3,4-Dimethoxy-4'-nitrobenzophenone

3,4-Dimethoxy-4'-nitrobenzophenone was prepared analogously to 3,4-dimethoxy-3'-nitrobenzophenone using veratrole (3.8 mL, 30 mmol), aluminum chloride (4.4 g, 33 mmol) and 4-nitrobenzoyl chloride (5.7 g, 30 mmol) with a 20 reaction time of 48 hours at reflux. The crude mixture was purified by flash column chromatography (silica gel, 4% ethyl acetate/methylene chloride) to afford 1.69 g (78%) of the product as a white solid: mp 172-173 °C; ¹H NMR (CDCl₃) δ 8.43-8.31 (m, 2 H), 7.97-7.86 (m, 2 H), 7.55-7.46 (m, 1 H), 7.40-7.30 (m, 1 H), 7.00-6.89 (m, 1 H), 3.99 (s, 3 H), 3.96 (s, 3 H); ¹³C NMR (CDCl₃) δ 193.4, 153.8, 149.4, 149.3, 143.8, 130.2, 130.0, 125.8, 123.4, 111.7, 109.9, 56.1, 56.0; Anal. Calcd for C₁₅H₁₃NO₅. Theoretical: C, 62.72; H, 4.56; N, 4.88. Found: C, 62.49; H, 4.68; N, 4.86.

B. 3-(3,4-Dimethoxyphenyl)-3-(4'-nitrophenyl)acrylonitrile

3-(3,4-Dimethoxyphenyl)-3-(4'-nitrophenyl)acrylonitrile was prepared analogously to methyl 3,3-bis-(3',4'-dimethoxyphenyl)acrylate using 3,4-dimethoxy-4'-nitrobenzophenone (4 g, 14 mmol), diethylcyanomethylphosphonate (2.5 mL, 15.4 mmol) and lithium hexamethyldisilazide (11.8 mL, 15.4 mmol, 1.3M) with a reaction 30 time of 17 hours at room temperature. The crude product was purified by

chromatography (silica gel, 3% hexane/methylene chloride) to afford 2.38 g (55%) of a mixture of the E and Z isomers as a yellow solid: mp 117.5-120 °C; ¹H NMR (CDCl₃) δ 8.40-8.20 (m, 4 H), 7.70-7.46 (m, 4 H), 7.06-6.75 (m, 6 H), 5.84 (s, 1 H), 5.70 (s, 1 H), 3.95 (s, 3 H), 3.93 (s, 3 H), 3.88 (s, 3 H), 3.85 (s, 3 H); ¹³C NMR (CDCl₃) δ 160.3, 151.7, 151.1, 149.2, 148.9, 148.7, 148.5, 148.5, 143.5, 130.6, 129.9, 129.6, 128.2, 123.7, 123.1, 122.2, 117.4, 117.3, 112.3, 111.0, 110.5, 96.2, 94.9, 56.0, 56.0; Anal. Calcd for C₁₇H₁₄N₂O₄. Theoretical: C, 65.80; H, 4.55; N, 9.03. Found: C, 65.45; H, 4.66; N, 8.82.

EXAMPLE 15

3-(4-Aminophenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile

3-(4-Aminophenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile was prepared analogously to 3-(3,4-dimethoxyphenyl)-3-(3-aminophenyl)acrylonitrile using 3-(3,4-dimethoxyphenyl)-3-(4-nitrophenyl)acrylonitrile (1.24 g, 4 mmol) and 0.15 g of 10% palladium on carbon catalyst in 100 mL of ethyl acetate. The crude mixture was purified by flash column chromatography (silica gel, 5% ethyl acetate/methylene chloride) to afford 0.19 g (17%) of a mixture of the E and Z isomers as a yellow solid: mp 150-152 °C; ¹H NMR (CDCl₃) δ 7.38-6.56 (m, 14 H); 5.51 (s, 1 H), 5.44 (s, 1 H), 3.97 (br s, 4 H), 3.93 (s, 3 H), 3.91 (s, 3 H), 3.85 (s, 3 H), 3.82 (s, 3 H); ¹³C NMR (CDCl₃) δ 162.8, 162.6, 150.8, 150.3, 148.8, 148.7, 148.5, 148.4, 132.4, 131.4, 130.1, 129.5, 129.9, 128.6, 126.7, 123.0, 122.1, 114.4, 114.3, 112.8, 111.6, 110.7, 90.3, 89.9, 56.0, 55.9; Anal. Calcd for C₁₇H₁₆N₂O₃. Theoretical: C, 72.84; H, 5.75; N, 9.99. Found: C, 72.79; H, 5.83; N, 9.59.

EXAMPLE 16

3,4-Dimethoxy-4'-aminobenzophenone

3,4-Dimethoxy-4'-aminobenzophenone was prepared analogously to 3,4-dimethoxy-3'-aminobenzophenone using 3,4-dimethoxy-4'-nitrobenzophenone (1 g, 3.5 mmol) and 0.1 g of 10% palladium on carbon catalyst in 110 mL of ethyl acetate. The crude product was purified by flash column chromatography (silica gel, 12% ethyl acetate/methylene chloride) to afford 0.32 g (36%) of the product as a yellow solid: mp 189-191 °C; ¹H NMR (CDCl₃) δ 7.80-7.62 (m, 2 H); 7.45-7.29 (m, 2 H), 6.96-6.80 (m, 1 H), 6.75-6.61 (m, 2 H), 4.14 (s, 2 H), 3.95 (s, 3 H), 3.93 (s, 3 H); ¹³C NMR (CDCl₃) δ 194.2, 152.2, 150.5, 148.8, 132.6, 131.3, 128.0, 124.3, 113.6, 112.3,

109.7, 56.0; Anal. Calcd for $C_{15}H_{15}NO_3$. Theoretical: C, 70.02; H, 5.88; N, 5.44. Found: C, 69.95; H, 6.18; N, 5.13.

EXAMPLE 17

3-(3,4-Dimethoxyphenyl)-3-(4-methylphenyl)acrylonitrile

5 A. 3,4-Dimethoxy-4'-methylbenzophenone

The title compound was prepared analogously to 3,4,3',4'-tetramethoxybenzophenone using veratrole (3.9 mL, 28 mmol), aluminum chloride (4.1 g, 31 mmol) and 4-methylbenzoyl chloride (4.6 mL, 29 mmol) with a reaction time of 6 hours at room temperature. The crude mixture was purified by flash column chromatography (silica gel, 2% ethyl acetate/methylene chloride) to afford 4.22 g (59%) of the product as a white solid: mp 121.5-122 °C; 1H NMR ($CDCl_3$) δ 7.70-7.67 (d, J = 8 Hz, 2 H), 7.48-7.26 (m, 4 H), 6.91-6.88 (d, J = 8.3 Hz, 1 H), 6.96 (s, 3 H), 3.94 (s, 3 H), 2.44 (s, 3 H); ^{13}C NMR ($CDCl_3$) δ 195.1, 152.6, 148.8, 142.4, 135.3, 130.3, 129.8, 128.7, 125.0, 112.0, 109.6, 55.9, 55.8, 21.4; Anal. Calcd for $C_{16}H_{16}O_3$. Theoretical: C, 74.98; H, 6.29. Found: C, 74.84; H, 6.43.

B. 3-(3,4-Dimethoxyphenyl)-3-(4-methylphenyl)acrylonitrile

3-(3,4-Dimethoxyphenyl)-3-(4-methylphenyl)acrylonitrile was prepared analogously to methyl 3,3-bis-(3,4-dimethoxyphenyl)acrylate using 3,4-dimethoxy-4'-methylbenzophenone (2.3 g, 9 mmol), diethylcyanomethylphosphonate (1.8 mL, 9.9 mmol) and lithium hexamethyldisilazide (10 mL, 9.9 mmol, 1M) with a reaction time of 22 hours at room temperature. The crude product was purified by chromatography (silica gel, 1% ethyl acetate/methylene chloride) to afford 1.83 g (73%) of a mixture of the E and Z isomers as a white solid: mp 83.5-86.5 °C; 1H NMR ($CDCl_3$) δ 7.35-7.20 (m, 8 H), 7.04-6.81 (m, 6 H), 5.62 (s, 1 H), 5.59 (s, 1 H), 3.90 (s, 3 H), 3.90 (s, 3 H), 3.88 (s, 3 H), 3.82 (s, 3 H), 2.41 (s, 3 H), 2.39 (s, 3 H); ^{13}C NMR ($CDCl_3$) δ 162.7, 162.6, 160.0, 150.4, 148.8, 148.5, 140.6, 140.1, 136.3, 134.1, 131.6, 129.5, 129.2, 129.0, 128.5, 123.0, 122.1, 118.4, 118.3, 112.6, 111.1, 110.7, 92.6, 92.4, 55.9, 55.9, 55.8, 21.3, 21.2; Anal. Calcd for $C_{18}H_{17}NO_2$. Theoretical: C, 77.40; H, 6.13; N, 5.01. Found: C, 77.64; H, 5.93; N, 5.01.

- 28 -

EXAMPLE 18

3-(4-Biphenylyl)-3-(3,4-dimethoxyphenyl)acrylonitrile

A. 3,4-Dimethoxy-4'-phenylbenzophenone

3,4-Dimethoxy-4'-phenylbenzophenone was prepared analogously to 3,4,3',4'-tetramethoxybenzophenone using veratrole (2.4 g, 17 mmol), aluminum chloride (2.5 g, 19 mmol) and 4-biphenylcarbonyl chloride (4 g, 18 mmol) with a reaction time of 24 hours at room temperature. The crude product was purified by flash column chromatography (silica gel, 2% ethyl acetate/methylene chloride) to afford 3.86 g (70%) of the product as a white solid: mp 103-104 °C; ¹H NMR (CDCl₃) δ 7.88-7.84 (m, 2 H), 7.73-7.64 (m, 4 H), 7.52-7.40 (m, 5 H), 6.93-6.90 (m, 1 H), 3.97 (s, 3 H), 3.96 (s, 3 H); ¹³C NMR (CDCl₃) δ 194.9, 152.9, 148.9, 144.5, 139.8, 136.8, 130.2, 130.2, 128.8, 127.9, 127.1, 126.7, 125.2, 112.0, 109.7, 55.9, 55.9; Anal. Calcd for C₂₁H₁₈O₃. Theoretical: C, 79.23; H, 5.70. Found: C, 78.91; H, 5.87.

B. 3-(4-Biphenylyl)-3-(3,4-dimethoxyphenyl)acrylonitrile

3-(4-Biphenylyl)-3-(3,4-dimethoxyphenyl)acrylonitrile was prepared analogously to methyl 3,3-bis-(3',4'-dimethoxyphenyl)acrylate using 3,4-dimethoxy-4'-phenylbenzophenone (2.33 g, 7.32 mmol), diethylcyanomethylphosphonate (1.5 mL, 8.1 mmol) and lithium hexamethyldisilazide (8.1 mL, 8.1 mmol, 1M) with a reaction time of 22 hours. The crude product was purified by chromatography (silica gel, 1% ethyl acetate/methylene chloride) to afford 1.76 g (70%) of a mixture of the E and Z isomers as a white solid: mp 132.0-134 °C; ¹H NMR (CDCl₃) δ 7.70-7.39 (m, 18 H), 7.10-6.80 (m, 6 H), 5.69 (s, 1 H), 5.68 (s, 1 H), 3.95 (s, 6 H), 3.93 (s, 3 H), 3.89 (s, 3 H), 3.85 (s, 3 H); ¹³C NMR (CDCl₃) δ 162.2, 151.1, 148.8, 148.6, 143.0, 142.6, 140.0, 137.9, 135.9, 131.4, 130.1, 129.3, 129.1, 128.8, 128.8, 127.9, 127.1, 127.0, 126.0, 126.9, 123.1, 122.2, 118.3, 118.2, 112.6, 111.1, 110.7, 93.2, 92.9, 56.0, 55.9, 55.8; Anal. Calcd for C₂₃H₁₉NO₂. Theoretical: C, 80.92; H, 5.61; N, 4.10. Found: C, 80.55; H, 5.80; N, 3.95.

EXAMPLE 19

3-(3,4-Dimethoxyphenyl)-3-(4'-fluorophenyl)acrylonitrile

3-(3,4-Dimethoxyphenyl)-3-(4'-fluorophenyl)acrylonitrile was prepared analogously to methyl 3,3-bis-(3,4-dimethoxyphenyl)acrylate using 3,4-dimethoxy-4'-

fluorobenzophenone (1.3 g, 5 mmol), diethylcyanomethylphosphonate (0.91 mL, 5.5 mmol) and lithium hexamethyldisilazide (5.5 mL, 5.5 mmol, 1M) with a reaction time of 22 hours at room temperature. The crude product was purified by chromatography (silica gel, 1% ethyl acetate/methylene chloride) to afford 2.38 g (55%) of a mixture 5 of the E and Z isomers as a white solid: mp 100-102°C; ¹H NMR (CDCl₃) δ 7.54-6.74 (m, 14 H), 5.67 (s, 1 H), 5.57 (s, 1 H), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.87 (s, 3 H), 3.83 (s, 3 H); ¹³C NMR (CDCl₃) δ 166.0, 165.6, 162.0, 161.6, 151.3, 150.7, 148.9, 148.7, 135.4, 135.4, 133.2, 133.1, 131.7, 131.6, 131.3, 130.7, 130.5, 129.2, 123.1, 122.1, 118.1, 118.0, 115.8, 115.8, 115.5, 115.4, 112.6, 111.0, 110.8, 93.4, 93.2, 56.0, 56.0, 10 55.9; Anal. Calcd for C₁₇H₁₄FNO₂. Theoretical: C, 72.07; H, 4.98; N, 4.94. Found: C, 71.91; H, 4.98; N, 4.79.

EXAMPLE 20

3-(3,4-Dimethoxyphenyl)-3-naphth-2-ylacrylonitrile (E and Z Isomers)

A. 2-(3,4-Dimethoxybenzoyl)naphthalene

15 2-(3,4-Dimethoxybenzoyl)naphthalene was prepared analogously to 3,4,3',4'-tetramethoxybenzophenone using veratrole (2.6 mL, 20 mmol), aluminum chloride (2.9 g, 22 mmol) and 2-naphthoyl chloride (3.9 g, 20 mmol) with a reaction time of 4 hours at reflux. The crude product was purified by flash column chromatography (silica gel, 2.5% ethyl acetate/methylene chloride) to afford 4.52 g (77%) of the 20 product as a white solid: mp 120-121.5 °C; ¹H NMR (CDCl₃) δ 8.24 (s, 1 H), 8.03-7.84 (m, 4 H), 7.68-7.40 (m, 4 H), 7.00-6.87 (m, 1 H), 3.97 (s, 3 H), 3.95 (s, 3 H); ¹³C NMR (CDCl₃) δ 195.5, 153.0, 149.0, 135.5, 134.9, 132.2, 131.0, 130.4, 129.2, 128.1, 128.0, 127.8, 126.7, 125.9, 125.4, 112.2, 109.8, 56.1, 56.0; Anal. Calcd for C₁₉H₁₆O₃. Theoretical: C, 78.06; H, 5.52. Found: C, 77.73; H, 5.69.

B. 3-(3,4-Dimethoxyphenyl)-3-naphth-2-ylacrylonitrile

3-(3,4-Dimethoxyphenyl)-3-naphth-2-ylacrylonitrile was prepared analogously to methyl 3,3-bis-(3',4'-dimethoxyphenyl)acrylate using 2-(3,4-dimethoxybenzoyl)naphthalene (2.9 g, 10 mmol), diethylcyanomethylphosphonate (1.8 mL, 11 mmol) and lithium hexamethyldisilazide (8.5 mL, 11 mmol, 1.3M) with a reaction time of 1 hour 30 at reflux. The crude product was purified by chromatography (silica gel, methylene chloride) to afford 2.93 g (93%) of a mixture of the E and Z isomers as a white solid:

- 30 -

mp 121-123 °C; ¹H NMR (CDCl₃) δ 8.11-6.78 (m, 20 H), 5.76 (s, 1 H), 5.75 (s, 1 H), 3.96 (s, 3 H), 3.92 (s, 3 H), 3.85 (s, 3 H), 3.80 (s, 3 H); ¹³C NMR (CDCl₃) δ 162.7, 162.7, 151.2, 150.6, 148.9, 148.7, 136.6, 134.5, 134.0, 133.8, 132.8, 131.5, 129.7, 129.4, 129.0, 128.6, 128.6, 128.3, 128.1, 127.7, 127.7, 127.4, 127.2, 126.8, 126.6, 5 125.4, 123.2, 122.2, 118.4, 118.2, 112.7, 111.1, 110.8, 93.9, 93.4, 56.0, 56.0, 55.9; Anal. Calcd for C₂₁H₁₇NO₂. Theoretical: C, 79.98; H, 5.43; N, 4.44. Found: C, 79.90; H, 5.65; N, 4.46.

EXAMPLE 21

10 **3-(3,4-Dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)acrylonitrile
(E and Z Isomers)**

A. 1-(3,4-Dimethoxybenzoyl)-3,4-methylenedioxybenzene

1-(3,4-Dimethoxybenzoyl)-3,4-methylenedioxybenzene was prepared analogously to 3,4,3',4'-tetramethoxybenzophenone using veratrole (1.3 mL, 10 mmol), aluminum chloride (1.5 g, 11 mmol) and piperonyloyl chloride (1.9 g, 10 mmol) with a reaction time of 2.5 hours at room temperature. The crude product was purified by flash column chromatography (silica gel, 5% ethyl acetate/methylene chloride) to afford 1.99 g (69%) of the product as a white solid: mp 164-165°C; ¹H NMR (CDCl₃) δ 7.46-7.26 (m, 4 H), 6.95-6.82 (m, 2 H), 6.06 (s, 2 H), 3.96 (s, 3 H), 3.94 (s, 3 H); ¹³C NMR (CDCl₃) δ 193.9, 152.7, 151.0, 148.9, 147.8, 132.4, 130.6, 20 126.1, 124.8, 112.2, 109.9, 109.7, 107.6, 101.7, 56.0, 56.0; Anal. Calcd for C₁₆H₁₄O₅. Theoretical: C, 67.13; H, 4.93. Found: C, 66.86; H, 5.11.

B. 3-(3,4-Dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)acrylonitrile

3-(3,4-Dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)acrylonitrile was prepared analogously to methyl 3,3-bis(3',4'-dimethoxyphenyl)acrylate using 1-(3,4-dimethoxybenzoyl)-3,4-methylenedioxybenzene (1.43 g, 5 mmol), diethylcyanomethylphosphonate (0.91 mL, 5.5 mmol) and lithium hexamethyldisilazide (4.2 mL, 5.5 mmol, 1.3M) with a reaction time of 1 hour at reflux and 24 hours at room temperature. The crude product was purified by chromatography (silica gel, 2% ethyl acetate/methylene chloride) to afford 0.79 g 30 (51%) of a mixture of the E and Z isomers as an off white solid: mp 121-123 °C; ¹H NMR (CDCl₃) δ 7.10-6.73 (m, 12 H), 6.13-5.94 (m, 4 H), 5.57 (s, 1 H), 5.53 (s, 1 H),

3.94 (s, 3 H), 3.92 (s, 3 H), 3.87 (s, 3 H), 3.84 (s, 3 H); ^{13}C NMR (CDCl_3) δ 162.3, 151.0, 150.5, 149.6, 149.1, 148.8, 148.5, 147.9, 133.2, 131.6, 130.8, 129.4, 124.3, 123.5, 123.1, 122.1, 118.5, 118.3, 112.6, 111.1, 110.7, 109.9, 108.5, 108.2, 101.6, 101.5, 92.2, 92.2, 56.0, 55.9, 55.9; Anal. Calcd for $\text{C}_{18}\text{H}_{15}\text{NO}_4$. Theoretical: C, 69.89; H, 4.89; N, 4.53. Found: C, 69.61; H, 5.01; N, 4.37.

EXAMPLE 22

3-(3,4-Dimethoxyphenyl)-3-pyridin-4-ylacrylonitrile (E and Z Isomers)

A. 4-(3,4-Dimethoxybenzoyl)pyridine

10 A hexane solution of butyl lithium (9 mL, 22 mmol, 2.5M) was slowly added to a stirring solution of 4-bromoveratrole (2.9 mL, 20 mmol) in 40 mL of tetrahydrofuran under nitrogen at -70 °C. After 15 minutes a solution of 4-cyanopyridine in 12 mL of tetrahydrofuran was added to the reaction mixture and stirring was continued for 45 minutes. The reaction was then allowed to warm to -10 °C and the reaction was 15 carefully quenched with hydrochloric acid (45 mL, 1N). The mixture was stirred for 30 minutes at room temperature. The pH was then adjusted to 12 with 50 mL of a 10% aqueous solution of sodium hydroxide. The mixture was extracted with ether (3 x 50 mL). The combined ethereal extracts were washed with brine (100 mL) then dried over magnesium sulfate and concentrated in vacuo to a brown solid. The crude 20 product was purified by flash column chromatography (silica gel, 3% methanol/methylene chloride) to afford after vacuum drying (60°C, 1 mm) 1.9 g (39%) of the product: mp 117-118°C; ^1H NMR (CDCl_3) δ 8.85-8.76 (m, 2 H), 7.60-7.50 (m, 3 H), 7.40-7.30 (m, 1 H), 6.97-6.88 (m, 1 H), 3.98 (s, 3 H), 3.96 (s, 3 H); ^{13}C NMR (CDCl_3) δ 193.7, 153.9, 150.1, 149.3, 145.2, 128.7, 125.9, 122.6, 111.5, 109.9, 25 56.1, 56.0; Anal. Calcd for $\text{C}_{14}\text{H}_{13}\text{NO}_3$. Theoretical: C, 69.12; H, 5.39; N, 5.76. Found: C, 69.05; H, 5.39; N, 5.85.

B. 3-(3,4-Dimethoxyphenyl)-3-pyridin-4-ylacrylonitrile

3-(3,4-Dimethoxyphenyl)-3-pyridin-4-ylacrylonitrile was prepared analogously to methyl 3,3-bis-(3',4'-dimethoxyphenyl)acrylate using 4-(3,4-dimethoxybenzoyl)pyridine (1 g, 4 mmol), diethylcyanomethylphosphonate (0.73 mL, 4.4 mmol) and lithium hexamethyldisilazide (3.4 mL, 4.4 mmol, 1.3M) with a reaction time of 24 hours at room temperature. The crude product was slurried in 10 mL of hexane. The mixture

was filtered, the solid was washed with hexane, air dried and then dried in vacuo to afford 0.91 g (85%) of a mixture of the E and Z isomers as an off white solid: mp 116-125°C; ¹H NMR (CDCl₃) δ 8.80-8.63 (m, 4 H), 7.40-7.20 (m, 4 H), 7.04-6.74 (m, 6 H), 5.81 (s, 1 H), 5.70 (s, 1 H), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.87 (s, 3 H), 3.84 (s, 3 H); 5 ¹³C NMR (CDCl₃) δ 160.1, 157.0, 151.6, 151.1, 150.3, 149.2, 148.9, 146.7, 144.9, 129.6, 127.8, 123.7, 123.1, 122.7, 122.1, 117.4, 117.1, 112.3, 111.0, 110.5, 96.1, 94.8, 56.0, 56.0; Anal. Calcd for C₁₆H₁₄N₂O₂. Theoretical: C, 72.17; H, 5.30; N, 10.52. Found: C, 72.35; H, 5.43; N, 10.47.

EXAMPLE 23

10 **3-(3,4-Dimethoxyphenyl)-3-pyridin-2-ylacrylonitrile**

A. 2-(3,4-Dimethoxybenzoyl)pyridine

2-(3,4-Dimethoxybenzoyl)pyridine was prepared analogously to 4-(3,4-dimethoxybenzoyl)pyridine using 2-cyanopyridine. The crude mixture was purified by flash column chromatography (silica gel, 1% methanol/methylene chloride) to afford after drying in vacuo (60°C, 1 mm) 1.67 g (34%) of the product: mp 91.5-93°C; ¹H NMR (CDCl₃) δ 8.76-8.70 (m, 1 H), 8.05-7.71 (m, 4 H), 7.55-7.45 (m, 1 H), 7.00-6.89 (m, 1 H), 3.96 (s, 3 H), 3.96 (s, 3 H); ¹³C NMR (CDCl₃) δ 192.1, 155.7, 153.3, 148.7, 148.2, 136.9, 128.9, 126.7, 125.7, 124.4, 112.6, 109.8, 56.0, 55.9; Anal. Calcd for C₁₄H₁₃NO₃. Theoretical: C, 69.12; H, 5.39; N, 5.76. Found: C, 68.96; H, 5.47; N, 5.66.

B. 3-(3,4-Dimethoxyphenyl)-3-pyridin-2-ylacrylonitrile

3-(3,4-Dimethoxyphenyl)-3-pyridin-2-ylacrylonitrile was prepared analogously to methyl 3,3-bis-(3',4'-dimethoxyphenyl)acrylate using 2-(3,4-dimethoxybenzoyl)-pyridine (1 g, 4 mmol), diethylcyanomethylphosphonate (0.73 mL, 4.4 mmol) and lithium hexamethyldisilazide (3.4 mL, 4.4 mmol, 1.3M) with a reaction time of 17 hours at room temperature. The crude product was purified by flash column chromatography (silica gel, 1% methanol/methylene chloride) to afford 0.8 g (75%) of a mixture of the E and Z isomers as a brown solid. The isomers were separated by additional purification (silica gel, 10% ethyl acetate/methylene chloride) to afford 30 pure samples of each of the isomers.

Isomer 1: mp 125-126 °C; ¹H NMR (CDCl₃) δ 8.75-8.65 (m, 1 H), 7.75-7.60 (m, 1 H), 7.41-7.16 (m, 2 H), 7.10-6.90 (m, 3 H), 6.52 (s, 1 H), 3.95 (s, 3 H), 3.89 (s, 3 H);

¹³C NMR (CDCl₃) δ 159.9, 154.9, 150.4, 149.9, 148.9, 136.7, 128.0, 124.6, 124.1, 122.6, 118.1, 112.4, 111.1, 97.8, 56.1, 56.0; Anal. Calcd for C₁₆H₁₄N₂O₂. Theoretical: C, 72.17; H, 5.30; N, 10.52. Found: C, 71.90; H, 5.28; N, 10.33.

5 Isomer 2: mp 134.5-135.5 °C; ¹H NMR (CDCl₃) δ 8.82-8.70 (m, 1 H), 7.88-7.76 (m, 1 H), 7.60-7.34 (m, 2 H), 6.94-6.80 (m, 3 H), 5.82 (s, 1 H), 3.91 (s, 3 H), 3.83 (s, 3 H); ¹³C NMR (CDCl₃) δ 160.8, 155.3, 151.2, 149.9, 149.0, 136.6, 130.2, 124.9, 124.3, 122.1, 117.6, 110.9, 95.4, 56.0; Anal. Calcd for C₁₆H₁₄N₂O₂. Theoretical: C, 72.17; H, 5.30; N, 10.52. Found: C, 72.13; H, 5.23; N, 10.40.

EXAMPLE 24

10 **3-(3,4-Dimethoxyphenyl)-3-(2-furyl)acrylonitrile (E and Z Isomers)**

A. **2-(3,4-Dimethoxybenzoyl)furan**

2-(3,4-Dimethoxybenzoyl)furan was prepared analogously to 3,4,3',4'-tetra-methoxybenzophenone using veratrole (1.3 mL, 10 mmol), aluminum chloride (1.5 g, 10 mmol) and 2-furoyl chloride (1.1 mL, 10 mmol) with a reaction time of 2 hours at reflux. The crude product was purified by flash column chromatography (silica gel, 4% ethyl acetate/methylene chloride) to afford 1.69 g (78%) of the product as a white solid: mp 112-114 °C; ¹H NMR (CDCl₃) δ 7.78-7.66 (m, 2 H), 7.59-7.52 (m, 1 H), 7.26-7.17 (m, 1 H), 6.96-6.90 (m, 1 H), 6.63-6.55 (m, 1 H), 3.97 (s, 3 H), 3.96 (s, 3 H); ¹³C NMR (CDCl₃) δ 180.9, 153.0, 152.5, 148.9, 146.5, 129.8, 124.0, 119.6, 112.0, 111.7, 110.0, 56.0, 55.9; Anal. Calcd for C₁₃H₁₂O₄. Theoretical: C, 67.23; H, 5.21. Found: C, 67.09; H, 5.21.

B. **3-(3,4-Dimethoxyphenyl)-3-(2-furyl)acrylonitrile**

3-(3,4-Dimethoxyphenyl)-3-(2-furyl)acrylonitrile was prepared analogously to methyl 3,3-bis(3',4'-dimethoxyphenyl)acrylate using 2-(3,4-dimethoxybenzoyl)-furan (0.87 g, 4 mmol), diethylcyanomethylphosphonate (0.73 mL, 4.4 mmol) and lithium hexamethyldisilazide (3.4 mL, 4.4 mmol, 1.3M) with a reaction time of 3 hours at room temperature. The crude product was purified by chromatography (silica gel, 2% ethyl acetate/methylene chloride) to afford 0.78 g (76%) of a mixture of the E and Z isomers as an off white solid: mp 78-82 °C; ¹H NMR (CDCl₃) δ 7.68-7.73 (m, 2 H), 7.16-6.75 (m, 7 H), 6.54-6.39 (m, 3 H), 5.87 (s, 1 H), 5.30 (s, 1 H), 3.93 (s, 3 H), 3.93 (s, 3 H), 3.91 (s, 3 H), 3.88 (s, 3 H); ¹³C NMR (CDCl₃) δ 152.0, 150.7, 150.5, 150.4, 149.3, 148.8, 148.7, 148.7, 145.2, 145.0, 129.6, 126.7, 122.1, 121.6, 118.1,

118.0, 116.5, 115.6, 112.5, 112.1, 112.0, 111.5, 110.9, 110.8, 90.5, 90.2, 55.9, 55.9, 55.9, 55.8; Anal. Calcd for $C_{15}H_{13}NO_3$. Theoretical: C, 70.58; H, 5.13; N, 5.49. Found: C, 70.61; H, 5.09; N, 5.18.

EXAMPLE 25

5 3-(3,4-Diethylphenyl)-3-phenylacrylonitrile (E and Z Isomers)

A. 3,4-Diethylbenzophenone

To a stirred ice bath cooled solution of diethylbenzene (1.7 mL, 10 mmol) in methylene chloride (30 mL) under nitrogen was added aluminum chloride (2.93 g, 22 mmol). A slight exotherm resulted. To the resulting reaction mixture was added 10 benzoyl chloride (1.2 mL, 10 mmol). The reaction mixture was allowed to warm to room temperature and was then stirred at room temperature for 1.5 hours. The reaction mixture was poured into 60 mL of iced water and stirred for 20 minutes. The resulting mixture was extracted with methylene chloride (2 x 40 mL). The combined extracts were dried over magnesium sulfate and concentrated in vacuo to afford the 15 crude product as an orange oil. The crude product was purified by flash column chromatography (silica gel, 2.5 % ethyl acetate/hexane) to afford 1.22 g (51%) of the product as a yellow oil: 1H NMR ($CDCl_3$) δ 7.85-7.41 (m, 7 H), 7.30-7.20 (m, 1 H) 2.83-2.61 (m, 4 H), 1.35-1.17 (m, 6 H); ^{13}C NMR ($CDCl_3$) δ 196.8, 147.0, 141.9, 138.1, 135.3, 132.1, 132.1, 130.1, 130.0, 128.1, 128.1, 25.6, 25.4, 15.1, 15.0; Anal. 20 Calcd for $C_{17}H_{18}O$. Theoretical: C, 85.67; H, 7.61. Found: C, 85.38; H, 7.42.

B. 3-(3,4-Diethylphenyl)-3-phenylacrylonitrile

3-(3,4-Diethylphenyl)-3-phenylacrylonitrile was prepared analogously to methyl 3,3-bis-(3,4-dimethoxyphenyl)acrylate using 3,4-diethylbenzophenone (0.95 g, 4 mmol), diethylcyanomethylphosphonate (0.73 mL, 4.4 mmol) and lithium hexamethyldisilazide (3.4 mL, 4.4 mmol, 1.3M) with a reaction time of 2 hours at room 25 temperature. The crude product was purified by flash chromatography (silica gel, 8% ethyl acetate/methylene chloride) to afford an oil which was stirred in hexane until it solidified. The resulting slurry was filtered, the solid washed with hexane, air dried and then dried in vacuo to afford 0.6 g (57%) of a mixture of the E and Z isomers as a 30 white solid: mp 63-64 °C; 1H NMR ($CDCl_3$) δ 7.51-6.99 (m, 16 H), 5.72 (s, 2 H), 2.76-2.55 (m, 8 H), 1.32-1.14 (m, 12 H); ^{13}C NMR ($CDCl_3$) δ 163.3, 144.7, 142.2, 137.3,

136.5, 130.2, 129.8, 129.6, 128.6, 128.5, 128.4, 128.3, 127.2, 126.2, 118.2, 93.9, 93.7, 25.5, 25.3, 15.2, 15.0.

EXAMPLE 26

3-(3,4-Diethylphenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile

5 A. 3',4'-Diethyl-3,4-dimethoxybenzophenone

3',4'-Diethyl-3,4-dimethoxybenzophenone was prepared analogously to 3,4-diethylbenzophenone using diethylbenzene (2.5 mL, 15 mmol), aluminum chloride (2.2 g, 16.5 mmol) and 3,4-dimethoxybenzoyl chloride (3 g, 15 mmol) with a reaction time of 3 hours at reflux. The crude product was purified by flash column chromatography (silica gel, 1.5 % ethyl acetate/hexane) to afford 0.84g (20%) of the product as an orange solid: mp 60-61 °C; ¹H NMR (CDCl₃) δ 7.74-7.15 (m, 5 H), 7.00-6.80 (m, 1 H) 3.96 (s, 3 H), 3.94 (s, 3 H), 2.93-2.60 (m, 4 H), 1.43-1.15 (m, 6 H); ¹³C NMR (CDCl₃) δ 195.5, 152.7, 148.8, 146.3, 141.7, 135.9, 130.6, 129.8, 128.0, 127.7, 125.1, 112.2, 109.7, 56.0, 25.6, 25.4, 15.1, 15.0; Anal. Calcd for C₁₉H₂₂O₃. Theoretical: C, 76.48; H, 7.43. Found: C, 76.53; H, 7.34.

B. 3-(3,4-Diethylphenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile

3-(3,4-Diethylphenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile was prepared analogously to methyl 3,3-bis-(3,4-dimethoxyphenyl)acrylate using 3',4'-diethyl-3,4-dimethoxybenzophenone (0.51 g, 1.7 mmol), diethylcyanomethylphosphonate (0.31 mL, 1.9 mmol) and lithium hexamethyldisilazide (1.4 mL, 1.9 mmol, 1.3M) with a reaction time of 60 hours at room temperature. The crude product was purified by chromatography (silica gel, 1% ethyl acetate/methylene chloride) to afford an oil which was stirred in hexane until it solidified. The resulting slurry was filtered, the solid washed with hexane, air dried, and dried in vacuo to afford 0.31 g (57%) of a mixture of the E and Z isomers as an off white solid: mp 78-82 °C; ¹H NMR (CDCl₃) δ 7.30-6.75 (m, 12 H), 5.61 (s, 1 H), 5.60 (s, 1 H), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.87 (s, 3 H), 3.83 (s, 3 H), 2.80-2.59 (m, 8 H), 1.35-1.14 (m, 12 H); ¹³C NMR (CDCl₃) δ 163.0, 163.0, 151.0, 150.5, 148.8, 148.6, 144.6, 143.9, 142.1, 141.8, 136.8, 134.5, 131.9, 129.7, 128.6, 128.5, 128.2, 127.3, 126.3, 123.2, 122.2, 118.7, 118.6, 112.8, 111.3, 110.7, 92.5, 92.2, 56.1, 56.0, 25.5, 25.4, 25.4, 25.3, 15.3, 15.2, 15.0, 14.9;

Anal. Calcd for $C_{21}H_{23}NO_2$. Theoretical: C, 78.47; H, 7.21; N, 4.36. Found: C, 77.80; H, 7.25; N, 4.68.

EXAMPLE 27

4-(3-Ethoxy-4-methoxyphenyl)-4-phenyl-3-butan-2-one

5 To a suspension of cuprous cyanide (0.21 g, 2.3 mmol) in tetrahydrofuran (8 mL) at -70 °C under nitrogen was added a cyclohexyl/ether solution of phenyl lithium (2.6 mL, 4.6 mmol, 1.8M). After 45 minutes a solution of 4-(3-ethoxy-4-methoxyphenyl)-3-buten-2-one (0.51 g, 2.3 mmol) in 10 mL of tetrahydrofuran was slowly added to the reaction mixture. After 1 hour at -78 °C the mixture was allowed to warm to room 10 temperature. The reaction mixture was then carefully quenched with 10 mL of an aqueous solution of ammonium chloride. The resulting mixture was extracted with methylene chloride (3 x 10 mL). The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to afford 0.7 g of the crude product. The crude product was purified by chromatography (silica gel, 2% ethyl 15 acetate/methylene chloride) to afford 0.41 g (60%) of the product as an oil which solidified: mp 57-58 °C; 1H NMR ($CDCl_3$) δ 7.31-7.13 (m, 5 H), 6.83-6.69 (m, 3 H), 4.48 (t, J = 7.5 Hz, 1 H), 4.03 (q, J = 7 Hz, 2 H), 3.82 (s, 3 H), 3.13 (d, J = 7.5 Hz, 2 H), 2.07 (s, 3 H), 1.41 (t, J = 7 Hz, 3 H); ^{13}C NMR ($CDCl_3$) δ 207.0, 148.2, 148.0, 144.2, 136.4, 128.6, 127.6, 126.4, 119.4, 113.0, 111.5, 64.3, 55.9, 49.9, 45.6, 30.6, 20 14.8; Anal. Calcd for $C_{19}H_{22}O_3$. Theoretical: C, 76.48; H, 7.43. Found: C, 76.81; H, 7.44.

EXAMPLE 28

3-(3,4-Dimethoxyphenyl)-3-(naphth-1-yl)acrylonitrile

1-(3,4-Dimethoxybenzoyl)naphthalene was prepared analogously to 3,4,3',4'-tetramethoxybenzophenone using veratrole (1.3 mL, 10 mmol), aluminum chloride (1.5 g, 11 mmol) and 1-naphthoyl chloride (1.5 mL, 10 mmol) with a reaction time of 24 hours at room temperature. The crude product was purified by flash column chromatography (silica gel, 2.5% ethyl acetate/methylene chloride) to afford 1.85 g (63%) of the product as a white solid: mp 92.5-94.5°C; 1H NMR ($CDCl_3$) δ 8.06-7.84 25 (m, 3 H), 7.80-7.39 (m, 5 H), 7.31-7.21 (m, 1 H), 6.84-6.74 (m, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H); ^{13}C NMR ($CDCl_3$) δ 196.6, 153.5, 149.0, 136.8, 133.6, 131.1, 130.9,

130.5, 128.2, 126.9, 126.7, 126.3, 126.3, 125.6, 124.3, 111.3, 109.7, 56.0, 55.9; Anal. Calcd for C₁₉H₁₆O₃. Theoretical: C, 78.06; H, 5.52. Found: C, 77.97; H, 5.66.

3-(3,4-Dimethoxyphenyl)-3-(naphth-1-yl)acrylonitrile is prepared in a fashion similar to that described in Example 20.

5

EXAMPLE 29

3-(3,4-Dimethoxyphenyl)-3-(2,5-dichlorophenyl)acrylonitrile

2',5'-Dichloro-3,4-dimethoxybenzophenone was prepared analogously to 3,4,3',4'-tetramethoxybenzophenone using veratrole (2.15 mL, 15 mmol), aluminum chloride (2.2 g, 16.5 mmol) and 2,5-dichlorobenzoyl chloride (1.9 mL, 15 mmol) with a reaction time of 3 hours at reflux. The crude product was purified by flash column chromatography (silica gel, 2.5% ethyl acetate/methylene chloride) to afford 3.88 g (83%) of the product as a white solid: mp 129-130°C; ¹H NMR (CDCl₃) δ 7.65-7.56 (m, 1 H), 7.41-7.12 (m, 4 H), 6.89-6.81 (m, 1 H), 3.96 (s, 3 H), 3.94 (s, 3 H); ¹³C NMR (CDCl₃) δ 191.1, 154.4, 149.6, 137.9, 132.0, 130.5, 128.7, 128.0, 125.7, 110.2, 56.1, 56.0; Anal. Calcd for C₁₅H₁₂Cl₂O₃. Theoretical: C, 57.90; H, 3.89. Found: C, 57.58; H, 3.87.

3-(3,4-Dimethoxyphenyl)-3-(2,5-dichlorophenyl)acrylonitrile is prepared in an analogous fashion as described in Example 26 starting with 5'-dichloro-3,4-dimethoxybenzophenone.

EXAMPLE 30

2',6',3,4-Tetramethoxybenzophenone

2',6',3,4-Tetramethoxybenzophenone was prepared analogously to 3,4,3',4'-tetramethoxybenzophenone except using veratrole (1.3 mL, 10 mmol), aluminum chloride (1.47 g, 11 mmol) and 2,6-dimethoxybenzoyl chloride (2.0 mL, 10 mmol) with a reaction time of 24 hours at room temperature. The crude mixture was purified by flash column chromatography (silica gel, 4% ethyl acetate/methylene chloride) to afford 2.11 g (70%) of the product as a white solid: mp 128-129 °C; ¹H NMR (CDCl₃) δ 7.66-7.60 (m, 1 H), 7.40-7.20 (m, 2 H), 6.88-6.79 (m, 1 H), 6.67-6.65 (m, 2 H), 3.93 (s, 3 H), 3.91 (s, 3 H), 3.71 (s, 6 H); ¹³C NMR (CDCl₃) δ 193.8, 157.4, 153.4,

- 38 -

148.9, 130.9, 130.5, 125.3, 118.0, 110.2, 109.9, 104.0, 55.9, 55.8; Anal. Calcd for C₁₇H₁₈O₅. Theoretical: C, 67.54; H, 6.00. Found: C, 66.51; H, 5.91.

3-(3,4-Dimethoxyphenyl)-3-(2,6-dimethoxyphenyl)acrylonitrile is prepared in an analogous fashion as described in Example 10 starting with 2',6',3,4-tetramethoxybenzophenone.

EXAMPLE 31

Tablets, each containing 50 milligrams of active ingredient, can be prepared in the following manner:

<u>Constituents</u> (for 1000 tablets)	
10	active ingredient 50.0 grams
	lactose 50.7 grams
	wheat starch 7.5 grams
	polyethylene glycol 6000 5.0 grams
	talc 5.0 grams
15	magnesium stearate 1.8 grams
	demineralized water q.s.

The solid ingredients are first forced through a sieve of 0.6 mm mesh width. The active ingredient, the lactose, the talc, the magnesium stearate and half of the starch then are mixed. The other half of the starch is suspended in 40 milliliters of water and this suspension is added to a boiling solution of the polyethylene glycol in 100 milliliters of water. The resulting paste is added to the pulverulent substances and the mixture is granulated, if necessary with the addition of water. The granulate is dried overnight at 35°C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 6 mm diameter which are concave on both sides.

EXAMPLE 32

Tablets, each containing 100 milligrams of active ingredient, can be prepared in the following manner:

<u>Constituents</u> (for 1000 tablets)	
30	active ingredient 100.0 grams
	lactose 100.0 grams
	wheat starch 47.0 grams
	magnesium stearate 3.0 grams

All the solid ingredients are first forced through a sieve of 0.6 mm mesh width. The active ingredient, the lactose, the magnesium stearate and half of the starch then are mixed. The other half of the starch is suspended in 40 milliliters of water and this suspension is added to 100 milliliters of boiling water. The resulting paste is added to 5 the pulverulent substances and the mixture is granulated, if necessary with the addition of water. The granulate is dried overnight at 35°C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 6 mm diameter which are concave on both sides.

EXAMPLE 33

10 Tablets for chewing, each containing 75 milligrams of active ingredient, can be prepared in the following manner:

<u>Composition (for 1000 tablets)</u>		
	active ingredient	75.0 grams
	mannitol	230.0 grams
15	lactose	150.0 grams
	talc	21.0 grams
	glycine	12.5 grams
	stearic acid	10.0 grams
	saccharin	1.5 grams
20	5% gelatin solution.....	q.s.

All the solid ingredients are first forced through a sieve of 0.25 mm mesh width. The mannitol and the lactose are mixed, granulated with the addition of gelatin solution, forced through a sieve of 2 mm mesh width, dried at 50°C and again forced through a sieve of 1.7 mm mesh width. The active ingredient, the glycine and the saccharin are 25 carefully mixed, the mannitol, the lactose granulate, the stearic acid and the talc are added and the whole is mixed thoroughly and compressed to form tablets of approximately 10 mm diameter which are concave on both sides and have a breaking groove on the upper side.

- 40 -

EXAMPLE 34

Tablets, each containing 10 milligrams of active ingredient, can be prepared in the following manner:

<u>Composition</u> (for 1000 tablets)	
5	active ingredient 10.0 grams
	lactose 328.5 grams
	corn starch 17.5 grams
	polyethylene glycol 6000 5.0 grams
	talc 25.0 grams
10	magnesium stearate 4.0 grams
	demineralized water q.s.

The solid ingredients are first forced through a sieve of 0.6 mm mesh width. Then the active ingredient, lactose, talc, magnesium stearate and half of the starch are intimately mixed. The other half of the starch is suspended in 65 milliliters of water and 15 this suspension is added to a boiling solution of the polyethylene glycol in 260 milliliters of water. The resulting paste is added to the pulverulent substances, and the whole is mixed and granulated, if necessary with the addition of water. The granulate is dried overnight at 35°C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 10 mm diameter which are concave on both sides and 20 have a breaking notch on the upper side.

EXAMPLE 35

Gelatin dry-filled capsules, each containing 100 milligrams of active ingredient, can be prepared in the following manner:

<u>Composition</u> (for 1000 capsules)	
25	active ingredient 100.0 grams
	microcrystalline cellulose 30.0 grams
	sodium lauryl sulphate 2.0 grams
	magnesium stearate 8.0 grams

The sodium lauryl sulphate is sieved into the active ingredient through a sieve of 30 0.2 mm mesh width and the two components are intimately mixed for 10 minutes. The microcrystalline cellulose is then added through a sieve of 0.9 mm mesh width and the whole is again intimately mixed for 10 minutes. Finally, the magnesium stearate is added through a sieve of 0.8 mm width and, after mixing for a further 3 minutes, the

mixture is introduced in portions of 140 milligrams each into size 0 (elongated) gelatin dry-fill capsules.

EXAMPLE 36

A 0.2% injection or infusion solution can be prepared, for example, in the following 5 manner:


active ingredient	5.0 grams
sodium chloride	22.5 grams
phosphate buffer pH 7.4	300.0 grams
demineralized water to 2500.0 milliliters	

10 The active ingredient is dissolved in 1000 milliliters of water and filtered through a microfilter or slurried in 1000 mL of H₂O. The buffer solution is added and the whole is made up to 2500 milliliters with water. To prepare dosage unit forms, portions of 1.0 or 2.5 milliliters each are introduced into glass ampoules (each containing respectively 2.0 or 5.0 milligrams of active ingredient).

1 What is claimed is:

2

3 1. A compound of the formula:



4

5 in which:

6 (a) X is -O- or -(C_nH_{2n})- in which n has a value of 0, 1, 2, or 3, and R¹ is alkyl of one
7 to 10 carbon atoms, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl
8 of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms, or

9 (b) X is -CH= and R¹ is alkylidene of up to 10 carbon atoms, monocycloalkylidene of
10 up to 10 carbon atoms, or bicycloalkylidene of up to 10 carbon atoms;

11 R² is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy,
12 carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower
13 alkyl, lower alkylidenemethyl, lower alkoxy, or halo;

14 R³ is (i) phenyl, unsubstituted or substituted with 1 or more substituents each selected
15 independently from nitro, cyano, halo, trifluoromethyl, carbethoxy,
16 carbomethoxy, carbopropoxy, acetyl, carbamoyl, or carbamoyl substituted with
17 alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino
18 substituted with an alkyl of 1 to 5 carbon atoms, alkyl of up to 10 carbon
19 atoms, cycloalkyl of up to 10 carbon atoms, alkoxy of up to 10 carbon atoms,
20 cycloalkoxy of up to 10 carbon atoms, alkylidenemethyl of up to 10 carbon
21 atoms, cycloalkylidenemethyl of up to 10 carbon atoms, phenyl, or
22 methylenedioxy; (ii) pyridine, substituted pyridine, pyrrolidine, imidazole,
23 naphthalene, or thiophene; (iii) cycloalkyl of 4 - 10 carbon atoms, unsubsti-
24 tuted or substituted with 1 or more substituents each selected independently
25 from the group consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy,
26 carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy,
27 amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10
28 carbon atoms, phenyl;

1 each of R⁴ and R⁵ taken individually is hydrogen or R⁴ and R⁵ taken together are a
 2 carbon-carbon bond;

3 Y is -COZ, -C≡N, or lower alkyl of 1 to 5 carbon atoms;

4 Z is -OH, -NR⁶R⁶, -R⁷, or -OR⁷;


5 R⁶ is hydrogen or lower alkyl; and

6 R⁷ is alkyl or benzyl.

7 2. A compound according to claim 1 in which R¹ is alkyl, monocycloalkyl of up to
 8 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to
 9 10 carbon atoms; X is -(CH₂)_n- or -O-, where n = 0, 1, 2, or 3; R² is hydrogen, nitro,
 10 cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl,
 11 acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, halo; and R⁴, R⁵, Y, Z, R⁶,
 12 and R⁷ are as therein defined.


13 3. A compound according to claim 1 in which R³ is (i) phenyl or naphthalene,
 14 unsubstituted or substituted with 1 or more substituents each selected independently
 15 from nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy,
 16 acetyl, carbamoyl, or carbamoyl substituted with alkyl of 1 to 3 carbon atoms, acetoxy,
 17 carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 5 carbon atoms, alkyl
 18 or cycloalkyl of 1 to 10 carbon atoms, alkoxy or cycloalkoxy of 1 to 10 carbon atoms; or
 19 (ii) cycloalkyl of 4 to 10 carbon atoms, unsubstituted or substituted with one or more
 20 substituents each selected independently from the group consisting of nitro, cyano, halo,
 21 trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy,
 22 carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1
 23 to 10 carbon atoms, or phenyl.

24 4. A compound according to claim 1 which is a nitrile of the formula:



25
26
27 or

- 44 -



1


2 wherein:

3 (a) X is -O- or -(C_nH_{2n})- in which n has a value of 0, 1, 2, or 3, and R¹ is alkyl of up
4 to 10 carbon atoms, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl
5 of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms, or
6 (b) X is -CH=, and R¹ is alkylidene of up to 10 carbon atoms or
7 monocycloalkylidene of up to 10 carbon atoms;

8 R² is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy,
9 carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower
10 alkyl, lower alkoxy, or halo; and

11 R³ is (i) phenyl or naphthyl, unsubstituted or substituted with 1 or more substituents
12 each selected independently from nitro, cyano, halo, trifluoromethyl,
13 carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, or carbamoyl
14 substituted with alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy,
15 amino, amino substituted with an alkyl of 1 to 5 carbon atoms, alkyl or
16 cycloalkyl of 1 to 10 carbon atoms, alkoxy or cycloalkoxy of 1 to 10 carbon
17 atoms; or (ii) cycloalkyl of 4 to 10 carbon atoms, unsubstituted or substituted
18 with one or more substituents each selected independently from the group
19 consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy,
20 carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino,
21 substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon
22 atoms, or phenyl.

23 5. A compound according to claim 1 which is an alcanoic acid derivative of the
24 formula:



25

- 45 -

1

or

2

3 wherein:


4 (a) X is -O- or -(C_nH_{2n})- in which n has a value of 0, 1, 2, or 3, and R¹ is alkyl of up
5 to 10 carbon atoms, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl
6 of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms, or
7 (b) X is -CH=, and R¹ is alkylidene of up to 10 carbon atoms or
8 monocycloalkylidene of up to 10 carbon atoms;

9 R² is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy,
10 carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower
11 alkyl, lower alkoxy, or halo;

12 R³ is (i) phenyl or naphthyl, unsubstituted or substituted with one or more
13 substituents each selected independently from nitro, cyano, halo,
14 trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl,
15 or carbamoyl substituted with alkyl of 1 to 3 carbon atoms, acetoxy, carboxy,
16 hydroxy, amino, amino substituted with an alkyl of 1 to 5 carbon atoms, alkyl
17 or cycloalkyl of 1 to 10 carbon atoms, alkoxy or cycloalkoxy of 1 to 10 carbon
18 atoms; or (ii) cycloalkyl of 4 to 10 carbon atoms, unsubstituted or substituted
19 with one or more substituents each selected independently from the group
20 consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy,
21 carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino,
22 substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon
23 atoms, or phenyl; and

24 Z is -OH, -NR⁶R⁶, R⁷ or -OR⁷ in which R⁶ is hydrogen or lower alkyl; and R⁷ is
25 alkyl or benzyl.

26 6. A compound according to claim 1 which is 3,3-bis-(3,4-dimethoxyphenyl)-
27 acrylonitrile, 3,3-bis-(3-ethoxy-4-methoxyphenyl)acrylonitrile, methyl 3,3-bis-(3-eth-
28 oxy-4-methoxyphenyl)-propenoate, methyl 3-(3-ethoxy-4-methoxyphenyl)-3-phenyl-



1 propenoate, 3-(3-propoxy-4-methoxyphenyl)-3-phenylacrylonitrile, 3-(3-ethoxy-4-
2 methoxyphenyl)-3-phenylacrylonitrile, 3,3-*bis*-(3-cyclopentoxy-4-methoxyphenyl)-
3 acrylonitrile, methyl 3-(3-cyclopentoxy-4-methoxyphenyl)-3-phenylpropenoate, 3-(3-
4 cyclopentoxy-4-methoxyphenyl)-3-phenylacrylonitrile, 3-(3-cyclopentoxy-4-meth-
5 oxyphenyl)-3-phenylpropene, 1-(3-cyclopentoxy-4-methoxyphenyl)-1-phenylpropane,
6 3-(3-cyclopentoxy-4-methoxyphenyl)-3-phenylpropanenitrile, methyl 3-(3-cyclopent-
7 oxy-4-methoxyphenyl)-3-phenylpropanoate, 3-(3-ethoxy-4-methoxyphenyl)-3-phen-
8 ylpropanenitrile, methyl 3-(3-ethoxy-4-methoxyphenyl)-3-phenylpropanoate, 3,3-*bis*-
9 (3,4-dimethoxyphenyl)propanenitrile, 3,3-*bis*-(3-ethoxy-4-methoxyphenyl)propane-
10 nitrile, 3-(3,4-dimethoxyphenyl)-3-phenylacrylonitrile, 3-(3-ethoxy-4-methoxyphen-
11 yl)-3-naphthylpropanenitrile, 3-(3,4-dimethoxyphenyl)-3-phenylpropanenitrile, or 3-
12 (3,4-dimethoxyphenyl)-3-(3-ethoxy-4-methoxyphenyl)propanenitrile.

13 7. A compound according to claim 1 which is 4,4-*bis*-(3,4-dimethoxyphenyl)but-
14 3-en-2-one; 4-(3,4-dimethoxyphenyl)-4-(3-ethoxy-4-methoxyphenyl)but-3-en-2-one;
15 4-(3,4-dimethoxyphenyl)-4-phenylbut-3-en-2-one; 4-(3,4-dimethoxyphenyl)-4-(3-cy-
16 clopentoxy-4-methoxyphenyl)but-3-en-2-one; 4-(3,4-dimethoxyphenyl)-4-(3-indan2-
17 yloxy-4-methoxyphenyl)but-3-en-2-one; 4-(3-ethoxy-4-methoxyphenyl)-4-(4-pyrid-
18 yl)but-3-en-2-one; 4-(3-ethoxy-4-methoxyphenyl)-4-(4-pyridyl)butan-2-one; 4-(3-cy-
19 clopentoxy-4-methoxyphenyl)-4-(4-pyridyl)but-3-en-2-one; 4-(3-cyclopentoxy-4-
20 methoxyphenyl)-4-(4-pyridyl)butan-2-one; methyl 3-(3-cyclopentoxy-4-methoxy-
21 phenyl)-3-(4-pyridyl)prop-2-enoate; methyl 3-(3-ethoxy-4-methoxyphenyl)-3-(4-pyr-
22 idyl)prop-2-enoate; methyl 3-(3-ethoxy-4-methoxyphenyl)-3-(4-pyridyl)propanoate;
23 4-(3-ethoxy-4-methoxyphenyl)-4-(2-furyl)but-3-en-2-one; 3-(3-ethoxy-4-methoxy-
24 phenyl)-3-(2-furyl)prop-2-enenitrile; 3-(3-ethoxy-4-methoxyphenyl)-3-(4-pyridyl)-
25 prop-2-enenitrile; 3-(3-ethoxy-4-methoxyphenyl)-3-(4-pyridyl)propanenitrile; 3-(3-
26 cyclopentoxy-4-methoxyphenyl)-3-(4-pyridyl)prop-2-enenitrile; 3-(3-cyclopentoxy-4-
27 methoxyphenyl)-3-(4-pyridyl)propanenitrile; 4-(3,4-dimethoxyphenyl)-4-(4-methoxy-
28 3-prop-1-enylphenyl)but-3-en-2-one; 4-(3,4-dimethoxyphenyl)-4-(4-methoxy-3-prop-
29 1-enylphenyl)but-3-en-2-one; 4,4-*bis*-(3,4-dimethoxyphenyl)butan-2-one; 4-(3,4-di-
30 methoxyphenyl)-4-(3-ethoxy-4-methoxyphenyl)butan-2-one; 4-(3,4-dimethoxyphen-
31 yl)-4-(3-cyclopentylidenemethyl)-4-methoxyphenyl)butan-2-one; 4-(3,4-dimethoxy-
32 phenyl)-4-(4-methoxy-3-prop-1-enylphenyl)butan-2-one; 4,4-*bis*-(3-ethoxy-4-meth-
33 oxyphenyl)but-3-en-2-one; 3-(3,4-dimethoxyphenyl)-3-(cyclopentylidenemethyl)-

1 4-methoxyphenyl)prop-2-enenitrile; 3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)-3-phenyl-prop-2-enenitrile; 1-(3,4-dimethoxyphenyl)-1-(3-ethoxy-4-methoxyphenyl)pentan-3-one; 1-(3,4-dimethoxyphenyl)-1-(3-ethoxy-4-methoxyphenyl)pent-1-en-3-one; 1,1-*bis*-(3,4-dimethoxyphenyl)pentan-3-one; 3-(3,4-dimethoxyphenyl)-3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)prop-2-enenitrile; 3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)-3-phenyl-propanenitrile; 3,3-*bis*-(3-(cyclopentylidene-methyl)-4-methoxyphenyl)propanenitrile; 3,3-*bis*-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)prop-2-enenitrile; 3-(3,4-dimethoxyphenyl)-3-(3-(cyclopentylidene-methyl)-4-methoxyphenyl)prop-2-enamide; 3-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)-3-phenylpropanamide; 3,3-*bis*-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)propanamide; 3,3-*bis*-(3-(cyclopentylidenemethyl)-4-methoxyphenyl)prop-2-enamide; 3-(3,4-dimethoxyphenyl)-3-(3-ethoxy-4-methoxyphenyl)prop-2-enamide; 3,3-*bis*-(3-ethoxy-4-methoxyphenyl)prop-2-enamide; 3,3-*bis*-(3,4-dimethoxyphenyl)prop-2-enamide; 3,3-*bis*-(3-ethoxy-4-methoxyphenyl)propanamide; 3,3-*bis*-(3,4-dimethoxyphenyl)propanamide; 4-(3,4-dimethoxyphenyl)-4-(4-methoxy-3-exo-norbornyloxyphenyl)but-3-en-2-one; 3-(3,4-dimethoxyphenyl)-3-(4-methoxy-3-exo-norbornyloxyphenyl)prop-2-enenitrile; 3-(3,4-dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)prop-2-enenitrile; 3-(4-aminophenyl)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile; or 3-(4-aminophenyl)-3-(3-ethoxy-4-dimethoxyphenyl)prop-2-enenitrile.

20 8. A method which comprises administering to a mammal an amount of a compound according to claim 1 which amount is effective to inhibit at least one of the enzymatic action of phosphodiesterase, the level of TNF_α and translocation of NFκB to the nucleus which comprises reducing the levels of phosphodiesterases, TNF_α and NFκB in mammals by administering thereto an effective amount of a compound according to claim 1.

25 9. A pharmaceutical composition comprising a compound according to claim 1 in an amount effective upon single or multiple dosage to inhibit at least one of the enzymatic action of phosphodiesterase, the level of TNF_α and translocation of NFκB to the nucleus, in combination with a pharmaceutical carrier.

INTERNATIONAL SEARCH REPORT

Internatinal Application No
PCT/US 97/14098

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 6 C07C255/37 C07C235/32 C07C69/612 C07C62/10 C07C49/175 A61K31/275 A61K31/215 A61K31/19 A61K31/16 A61K31/12				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols)				
IPC 6 C07C A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document, with indication, where appropriate, of the relevant passages			Relevant to claim No.
X	DE 42 20 983 A (BAYER AG) 5 January 1994 see examples VIII, XXII, XXVI, XXVII, XXXI, XXXIII and XXXIV --- DE 35 25 623 A (CELAMERCK GMBH & CO KG) 22 January 1987 see formulae II, VII and IX in parallel with Table I --- -/-/			1-5
X				1-7
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.		
*Special categories of cited documents:				
A document defining the general state of the art which is not considered to be of particular relevance		*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
E earlier document but published on or after the international filing date		*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
L document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.		
O document referring to an oral disclosure, use, exhibition or other means		*Z* document member of the same patent family		
P document published prior to the international filing date but later than the priority date claimed				
1 Date of the actual completion of the international search		Date of mailing of the international search report		
15 October 1997		26. 11. 97		
Name and mailing address of the ISA		Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Janus, S		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/14098

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ERICKSON, M. ET AL.: "Gaschromatographische Analyse von Ligninoxydationsprodukten. VII. Ein verbessertes Verfahren zur Charakterisierung von Ligninen durch Methylierung und oxydativen Abbau" ACTA CHEMICA SCANDINAVICA, vol. 27, no. 1, 1973, pages 127-140, XP002043682 see scheme on bottom of p. 134, compounds 40-46 ---	1-3
X	CHEMICAL ABSTRACTS, vol. 94, no. 25, 22 June 1981 Columbus, Ohio, US; abstract no. 208463b, MAMADZHANOV, A. ET AL.: "Condensation of pyrocatechol and its methyl ethers with alpha-ethyl- and alpha-phenylbenzyl alcohols in the presence of polyphosphoric acid" page 563; XP002043683 see abstract & "Deposited Doc. VINITI 3488" 1979 ---	1-3
X	CHEMICAL ABSTRACTS, vol. 83, no. 14, 6 October 1975 Columbus, Ohio, US; abstract no. 117388n, ZARUBIN, M. YA ET AL.: "Acid-base reactions of lignin with strong acids" page 192; XP002043684 see abstract & KHIM. DREV., vol. 1975, no. 3, 1975, pages 68-78, ---	1-3
X	CHEMICAL ABSTRACTS, vol. 72, no. 5, 2 February 1970 Columbus, Ohio, US; abstract no. 21510t, ABE, S. ET AL.: "beta-Arylcinnamonnitriles" page 293; XP002043685 see abstract & JP 44 026 659 A (...) 7 November 1969 ---	1-3
1		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/14098

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 69, no. 4, 22 July 1968 Columbus, Ohio, US; abstract no. 11533b, RYABYKH, V.I. ET AL.: "Reaction of lignin model compounds with resorcinol" page 1111; XP002043686 see abstract & ISV. VYSSH. UCHEB. ZAVED., LES. ZH., vol. 11, no. 1, 1968, pages 145-148,</p> <p style="text-align: center;">---</p>	1-3
X	<p>DATABASE CROSSFIRE Beilstein BRN 1350730, 1654892, 2170386, 2191496, 2663279,, 3064897, 3065899, 3067424, 3068278, 3070465, 3347953, 3367330, 3376758, 3378600, 3388840, 3389419, 3390797, 3398993, 3401028, : "3427095, 3429133, 3440376, 3448126, 3451855, 3457179, 3468591, 3479485, 4061082, 4202803, 4207544, 5452196, 5581750, 5585466, 5598082, 5600935, 5608241, 5618321, 5875898, 6519749, 6930574" XP002043687</p> <p style="text-align: center;">& "</p> <p style="text-align: center;">---</p>	1-3,5-7
X	<p>WO 96 21435 A (EURO CELTIQUE SA ;CAVALLA DAVID J (GB); CHASIN MARK (US); DOLBY LL) 18 July 1996 see the whole document</p> <p style="text-align: center;">---</p>	1-9
A	<p>WO 96 20926 A (CELGENE CORP ;MULLER GEORGE (US); SHIRE MARY (US); STIRLING DAVID) 11 July 1996</p> <p style="text-align: center;">---</p>	1-9
A	<p>WO 94 14800 A (CELLTECH LTD) 7 July 1994</p> <p style="text-align: center;">---</p>	1-9
A	<p>WO 94 14742 A (CELLTECH LTD) 7 July 1994</p> <p style="text-align: center;">----</p>	1-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/14098

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 8
because they relate to subject matter not required to be searched by this Authority, namely:
See further information sheet PCT/ISA/210

2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97 14098

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claim 8 is directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interna	Application No
PCT/US 97/14098	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
DE 4220983 A	05-01-94	AU 4006393 A CA 2099068 A CN 1082041 A CZ 9301174 A EP 0578002 A HU 65190 A JP 6065209 A MX 9303600 A NO 932132 A SK 66793 A US 5414008 A ZA 9304584 A		06-01-94 27-12-93 16-02-94 19-01-94 12-01-94 02-05-94 08-03-94 01-12-93 27-12-93 02-02-94 09-05-95 01-02-94
DE 3525623 A	22-01-87	EP 0208999 A		21-01-87
WO 9621435 A	18-07-96	US 5591776 A AU 4756696 A EP 0796093 A		07-01-97 31-07-96 24-09-97
WO 9620926 A	11-07-96	AU 4246396 A EP 0800514 A		24-07-96 15-10-97
WO 9414800 A	07-07-94	AU 678797 B AU 5709394 A EP 0626957 A JP 7504687 T US 5580888 A		12-06-97 19-07-94 07-12-94 25-05-95 03-12-96
WO 9414742 A	07-07-94	AU 680224 B AU 5709294 A CA 2129039 A CN 1092064 A CZ 9402034 A EP 0626939 A FI 943856 A GB 2279075 A,B HU 70559 A HU 9500330 A JP 7504442 T MX 9400175 A		24-07-97 19-07-94 07-07-94 14-09-94 15-12-94 07-12-94 22-08-94 21-12-94 30-10-95 30-10-95 18-05-95 29-07-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 97/14098

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9414742 A		NO 943091 A NZ 258982 A PL 304892 A US 5622977 A ZA 9309623 A	21-10-94 24-02-97 09-01-95 22-04-97 18-08-94